<doc>
  <docmeta id="113hr1919eh">
    <bill congress="113" type="hr" number="1919" version="eh"/>
    <revision size="125931" annotations="0" status="complete" id="20" commit-time="2014-03-21T15:10:13Z" committer="mbohmer" doc="113hr1919eh/20.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Engrossed-in-House" bill-type="olc" dms-id="HB830F70FF7E04CC7932F2128960E6408" public-private="public" stage-count="1"> 
<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 1919 EH: Safeguarding America’s Pharmaceuticals Act of 2013</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/"/>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="no">I</distribution-code> 
<congress>113th CONGRESS</congress> <session>1st Session</session> 
<legis-num>H. R. 1919</legis-num> 
<current-chamber display="no">IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<legis-type>AN ACT</legis-type> 
<official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.</official-title> 
</form> 
<legis-body id="H3854716CC3BD4827AEEA45A0EC9DA031" style="OLC"> 
<section id="H422CBBED90084520BCB9E4410711CCE3" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header> 
<subsection id="HE444B2CD049A4504B30B7D2820BAB4B7">
        <enum>(a)</enum>
        <header>Short title</header>
        <text display-inline="yes-display-inline">This Act may be cited as the <quote>
            <short-title>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
            </short-title>
          </quote>.</text>
      </subsection> 
<subsection id="H3FAD39DAA26D4F53861F3575D5F60791">
        <enum>(b)</enum>
        <header>Table of contents</header>
        <text display-inline="yes-display-inline">The table of contents of this Act is as follows:</text> 
<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration"> 
<toc-entry idref="H422CBBED90084520BCB9E4410711CCE3" level="section">Sec. 1. Short title.</toc-entry> 
<toc-entry idref="H526D6BCD88FF4955B5E8FF048ED0EFC6" level="section">Sec. 2. Pharmaceutical distribution supply chain.</toc-entry> 
<toc-entry idref="H5FB5AF949194479DA7725A68B6E54A64" level="section">Sec. 3. Enhanced drug distribution security.</toc-entry> 
<toc-entry idref="HC92C03A1E14A4091A405B1E94899365C" level="section">Sec. 4. National standards for wholesale distributors.</toc-entry> 
<toc-entry idref="H1829C4B465AD494D81140487175586F6" level="section">Sec. 5. National licensure standards for third-party logistics providers.</toc-entry> 
<toc-entry idref="H49245758A244454BA888E66E49BE87D3" level="section">Sec. 6. Penalties.</toc-entry> 
<toc-entry idref="HC438ED95D59F422AB9C707A32D1F9C46" level="section">Sec. 7. Uniform national policy.</toc-entry> 
<toc-entry idref="HB8F1F9C2B1C445ADAF7457B57816C0EB" level="section">Sec. 8 Electronic labeling.</toc-entry>
        </toc>
      </subsection>
    </section> 
<section id="H526D6BCD88FF4955B5E8FF048ED0EFC6">
      <enum>2.</enum>
      <header>Pharmaceutical distribution supply chain</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
          <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq</cato:entity-ref>.</external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H5EFD0B4309FB46959E45682F41B9EC60" style="OLC"> 
<subchapter id="HA1A32CAB66FA460C81C8E30505544439">
          <enum>H</enum>
          <header>Pharmaceutical Distribution Supply Chain</header> 
<section id="HB7ECA47D3C0D4968ABE9510B5E269355">
            <enum>581.</enum>
            <header>Definitions</header>
            <text display-inline="no-display-inline">In this subchapter:</text> 
<paragraph id="H4A38D047E97C42DC84CD9D48D31A36A9">
              <enum>(1)</enum>
              <header>Authorized</header>
              <text>The term <term>authorized</term> means—</text> 
<subparagraph id="H110F32588BB942649B1577E84CBE31DA">
                <enum>(A)</enum>
                <text>in the case of a manufacturer or repackager, having a valid registration in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>; and</text>
              </subparagraph> 
<subparagraph id="H4C55149CB7A845FE8215FE4D1F631E9B">
                <enum>(B)</enum>
                <text>in the case of a wholesale distributor, third-party logistics provider, or dispenser, licensed (as defined in this section).</text>
              </subparagraph>
            </paragraph> 
<paragraph id="HA5B8DFF097F04607B722599DCE023CFB">
              <enum>(2)</enum>
              <header>Dispenser</header>
              <text>The term <term>dispenser</term>—</text> 
<subparagraph id="HABE3EAD415C04E348D80AE3E2A895FB2">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:2/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>, means a retail pharmacy, hospital pharmacy, a group of chain pharmacies under common ownership and control, or any other person authorized by law to dispense or administer prescription drugs, to the extent such pharmacy, group, or person does not act as a wholesale distributor;</text>
              </subparagraph> 
<subparagraph id="H246085986C7C45698EE5E8CAD262A3C2">
                <enum>(B)</enum>
                <text>includes warehouses and distribution centers under common ownership or control of entities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> that are members of an affiliated group pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">
                    <external-xref legal-doc="usc" parsable-cite="usc/26/1504">section 1504(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref>, to the extent such warehouses and distribution centers do not act as a wholesale distributor; and</text>
              </subparagraph> 
<subparagraph id="H7E90D7130347453B9620CCC97D1277D3">
                <enum>(C)</enum>
                <text>does not include a person who only dispenses prescription drug product to be used in animals in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:a/p:5">section 512(a)(5)</cato:entity-ref>.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H85756B299EC74DB6B8FAEE1C9034A392">
              <enum>(3)</enum>
              <header>Disposition</header>
              <text>The term <term>disposition</term>, with respect to a prescription drug product within the possession and control of an entity—</text> 
<subparagraph id="HF0E4313C5AFD4483A2C2673B82FDB4C0">
                <enum>(A)</enum>
                <text>means the removal of such prescription drug product, or taking measures to prevent the introduction of such prescription drug product, from the pharmaceutical distribution supply chain; and</text>
              </subparagraph> 
<subparagraph id="H21E4B04B7D6C4679B2263F072CD6F3F9">
                <enum>(B)</enum>
                <text>may include disposal, return of the prescription drug product for disposal, or other appropriate handling and other actions such as retaining a sample of the prescription drug product for additional physical examination or laboratory analysis by a manufacturer or regulatory or law enforcement agency.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H454456288B224F4AA9A909367ED0940E">
              <enum>(4)</enum>
              <header>Distribute or distribution</header>
              <text>The terms <term>distribute</term> and <term>distribution</term> mean the sale, purchase, trade, delivery, handling, or storage of a prescription drug product.</text>
            </paragraph> 
<paragraph id="H70DC7F9CA46B425CB2FFB0183F2C4C99">
              <enum>(5)</enum>
              <header>Illegitimate prescription drug product</header>
              <text>The term <term>illegitimate prescription drug product</term> means a prescription drug product which a manufacturer has confirmed—</text> 
<subparagraph id="HBE3FB52AE5774A0198E581FDF601097D">
                <enum>(A)</enum>
                <text>is counterfeit, diverted, or stolen;</text>
              </subparagraph> 
<subparagraph id="HA8FC7B4652CC42E9AB800EE75818D8CA">
                <enum>(B)</enum>
                <text>is intentionally adulterated such that the prescription drug product would result in serious adverse health consequences or death to humans; or</text>
              </subparagraph> 
<subparagraph id="HB93FD9D693B149FC8079F8B994FB18AF">
                <enum>(C)</enum>
                <text>is otherwise unfit for distribution such that the prescription drug product is reasonably likely to cause serious adverse human health consequences or death.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="HDC6C6444A4074829ADF1F994BAC71B21">
              <enum>(6)</enum>
              <header>Licensed</header>
              <text>The term <term>licensed</term> means—</text> 
<subparagraph id="H7B76703CBC7B4670B68627805FC77E91">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">in the case of a wholesale distributor, having a valid license to make wholesale distributions consistent with the standards under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>;</text>
              </subparagraph> 
<subparagraph id="HA5BBAE04F80840338C17B78DEB9DBA05">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">in the case of a third-party logistics provider, having a valid license to engage in the activities of a third-party logistics provider in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref>; and</text>
              </subparagraph> 
<subparagraph id="HFDDEDC6070A441929458269A917CF965">
                <enum>(C)</enum>
                <text>in the case of a dispenser, having a valid license to dispense prescription drugs under State law.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H5ACC0D61ABC24EC3B58F0C7A61E31F20">
              <enum>(7)</enum>
              <header>Manufacturer</header>
              <text>The term <term>manufacturer</term> means, with respect to a prescription drug product—</text> 
<subparagraph id="HAB17FB834EB44811B069355F6DE49F1B">
                <enum>(A)</enum>
                <text>a person that holds an application approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or a license issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> for such prescription drug product, or if such prescription drug product is not the subject of an approved application or license, the person who manufactured the prescription drug product;</text>
              </subparagraph> 
<subparagraph id="HF18AE0E19CFD42BFBBB247847A7348EC">
                <enum>(B)</enum>
                <text>a co-licensed partner of the person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> that obtains the prescription drug product directly from the person described in such subparagraph; or</text>
              </subparagraph> 
<subparagraph id="H5D49E7FC364340E9A7E57D3B8B77F694">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">a person that—</text> 
<clause id="H3E5488EED6A1409C9AEBB68DFE123E70">
                  <enum>(i)</enum>
                  <text>is a member of an affiliated group (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">
                      <external-xref legal-doc="usc" parsable-cite="usc/26/1504">section 1504(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref>) to which a person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:B" proposed="true">(B)</cato:entity-ref> is also a member; and</text>
                </clause> 
<clause id="H51220DCE2F4C40B285CDF276A11032A9">
                  <enum>(ii)</enum>
                  <text>receives the prescription drug product directly from a person described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:7/sp:B" proposed="true">(B)</cato:entity-ref>.</text>
                </clause>
              </subparagraph>
            </paragraph> 
<paragraph id="HF9713F8B8D3C419F83A831AE80FCE306">
              <enum>(8)</enum>
              <header>Package</header> 
<subparagraph id="HBF07173A76544815AA78E5220162AE31">
                <enum>(A)</enum>
                <header>In general</header>
                <text display-inline="yes-display-inline">The term <term>package</term> means the smallest individual saleable unit of prescription drug product for distribution in interstate commerce by a manufacturer or repackager that is intended by the manufacturer for ultimate sale to the dispenser of such prescription drug product.</text>
              </subparagraph> 
<subparagraph id="H45B837B9E50E47899482E46DBF6D4116">
                <enum>(B)</enum>
                <header>Individual saleable unit</header>
                <text display-inline="yes-display-inline">The term <term>individual saleable unit</term> means the smallest container of prescription drug product introduced into interstate commerce by the manufacturer or repackager that is intended by the manufacturer for individual sale to a dispenser.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="HC7F4EA8101D141B1AF9426F31AAB6E3F">
              <enum>(9)</enum>
              <header>Prescription drug</header>
              <text>The term <term>prescription drug</term> means a drug for human use subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>.</text>
            </paragraph> 
<paragraph id="HDEC1E6499E024ED384386D01BE7F8A76">
              <enum>(10)</enum>
              <header>Prescription drug product</header>
              <text display-inline="yes-display-inline">The term <term>prescription drug product</term> means a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing (such as capsules, tablets, and lyophilized prescription drug products before reconstitution).</text>
            </paragraph> 
<paragraph id="H1F9F7D43374D46AC9CA5D05AE1C770F9">
              <enum>(11)</enum>
              <header>Prescription drug product identifier</header>
              <text>The term <term>prescription drug product identifier</term> means a standardized graphic that—</text> 
<subparagraph id="H8BB1EA3781B942F6A46BE4201B9CAD78">
                <enum>(A)</enum>
                <text>includes the standardized numerical identifier, lot number, and expiration date of a prescription drug product; and</text>
              </subparagraph> 
<subparagraph id="H993FD619EC434F4598C76FCA345B0543">
                <enum>(B)</enum>
                <text>is in both human-readable form and on a machine-readable data carrier that conforms to the standards developed by a widely recognized international standards development organization.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H4868A2352C6F4054942944BC420C9702">
              <enum>(12)</enum>
              <header>Quarantine</header>
              <text display-inline="yes-display-inline">The term <term>quarantine</term> means to store or identify a product, for the purpose of preventing distribution or transfer of the product, in a physically separate area clearly identified for such use, or through use of other procedures such as automated designation.</text>
            </paragraph> 
<paragraph id="H1F9F9211EA2A4B37AFEBEAC95296FA7D">
              <enum>(13)</enum>
              <header>Repackager</header>
              <text>The term <term>repackager</term> means a person who owns or operates an establishment that repacks and relabels a prescription drug product or package for further sale or distribution.</text>
            </paragraph> 
<paragraph id="H321DE12785914C9C8359077369542D89">
              <enum>(14)</enum>
              <header>Return</header>
              <text display-inline="yes-display-inline">The term <term>return</term> means providing prescription drug product to the authorized trading partner or trading partners from which such prescription drug product was purchased or received, or to a returns processor for handling of such prescription drug product.</text>
            </paragraph> 
<paragraph id="H0682B006566243BE9C2DDD9743DFF892">
              <enum>(15)</enum>
              <header>Returns processor</header>
              <text>The terms <term>returns processor</term> mean a person who owns or operates an establishment that provides for the disposition of or otherwise processes saleable and nonsaleable prescription drug product received from an authorized trading partner such that the prescription drug product may be processed for credit to the purchaser, manufacturer, seller, or disposed of for no further distribution.</text>
            </paragraph> 
<paragraph id="HBD0A93AD15504C5B87F2011FE6A07C96">
              <enum>(16)</enum>
              <header>Specific patient need</header>
              <text>The term <term>specific patient need</term>—</text> 
<subparagraph id="H532CA45FECE04B88BED9F7C6182FA103">
                <enum>(A)</enum>
                <text>means with respect to the transfer of a prescription drug product from one pharmacy to another, to fill a prescription for an identified patient; and</text>
              </subparagraph> 
<subparagraph id="HD1A9A760778F4554B6607643908DB845">
                <enum>(B)</enum>
                <text>does not include the transfer of a prescription drug product from one pharmacy to another for the purpose of increasing or replenishing stock in anticipation of a potential need.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H3960C4ED9F3049EBBB28B8F0BEE701DF">
              <enum>(17)</enum>
              <header>Standardized numerical identifier</header>
              <text display-inline="yes-display-inline">The term <term>standardized numerical identifier</term> means a set of numbers or characters that—</text> 
<subparagraph id="H6D4A5A0BAC06409F90EDAF3FD2ACA204">
                <enum>(A)</enum>
                <text>is used to uniquely identify each package or homogenous case of the prescription drug product; and</text>
              </subparagraph> 
<subparagraph id="H4D684033C670460F926A7D1C1A452886">
                <enum>(B)</enum>
                <text>is composed of the National Drug Code that corresponds to the specific prescription drug product (including the particular package configuration) combined with a unique alphanumeric serial number of up to 20 characters.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="HD00D7DE36F7B4876902A0BF18B11AE0D">
              <enum>(18)</enum>
              <header>Suspect prescription drug product</header>
              <text>The term <term>suspect prescription drug product</term> means a prescription drug product for which there is reason to believe that such prescription drug product—</text> 
<subparagraph id="H2CA60E4F5B044CC289787C01361EF7FF">
                <enum>(A)</enum>
                <text>is potentially counterfeit, diverted, or stolen;</text>
              </subparagraph> 
<subparagraph id="H7867B1560AEC4EF5AF365ECBD092B197">
                <enum>(B)</enum>
                <text>is potentially intentionally adulterated such that the prescription drug product would result in serious adverse health consequences or death to humans; or</text>
              </subparagraph> 
<subparagraph id="H82707A650557467AA8B3C28272BE242A">
                <enum>(C)</enum>
                <text>appears otherwise unfit for distribution such that the prescription drug product would result in serious adverse health consequences or death to humans.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H0B47ABE22637470DBFBFB46690265FFA">
              <enum>(19)</enum>
              <header>Third-party logistics provider</header>
              <text>The term <term>third-party logistics provider</term> means an entity that provides or coordinates warehousing, distribution, or other logistics services of a prescription drug product in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of a prescription drug product, but does not take ownership of the prescription drug product, nor have responsibility to direct the sale or disposition of, the prescription drug product.</text>
            </paragraph> 
<paragraph id="H5B7D9B43B32842C8AC3881BC5D8DA89B">
              <enum>(20)</enum>
              <header>Trading partner</header>
              <text>The term <term>trading partner</term> means—</text> 
<subparagraph id="H60F2130E24BE44AD9781FDDCFCDADAF5">
                <enum>(A)</enum>
                <text>a manufacturer, repackager, wholesale distributor, or dispenser from whom a manufacturer, repackager, wholesale distributor, or dispenser accepts ownership of a prescription drug product or to whom a manufacturer, repackager, wholesale distributor, or dispenser transfers ownership of a prescription drug product; or</text>
              </subparagraph> 
<subparagraph id="H4D85894325994316A4A010B83D92AF24">
                <enum>(B)</enum>
                <text>a third-party logistics provider from whom a manufacturer, repackager, wholesale distributor, or dispenser accepts possession of a prescription drug product or to whom a manufacturer, repackager, wholesale distributor, or dispenser transfers possession of a prescription drug product.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H0751F2C31D0D41B99C99DD0AA4052E71">
              <enum>(21)</enum>
              <header>Transaction</header> 
<subparagraph id="H5826FF29242341A8943B1C350775BB4C">
                <enum>(A)</enum>
                <header>In general</header>
                <text>The term <term>transaction</term> means the transfer in interstate commerce of prescription drug product between persons in which a change of ownership occurs.</text>
              </subparagraph> 
<subparagraph id="HF2E35F14C9D34044A5DBB8BFD43B1B5A">
                <enum>(B)</enum>
                <header>Exemptions</header>
                <text>The term <term>transaction</term> does not include—</text> 
<clause id="H3008FB8747D347848FEB64DAEB2AD371">
                  <enum>(i)</enum>
                  <text display-inline="yes-display-inline">intracompany distribution of any prescription drug product, including between members of an affiliated group (as defined in 
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">
                      <external-xref legal-doc="usc" parsable-cite="usc/26/1504">section 1504(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref>);</text>
                </clause> 
<clause id="H5F9EF6C648D641FFB1E01FCE349A6374">
                  <enum>(ii)</enum>
                  <text>the distribution of a prescription drug product among hospitals or other health care entities that are under common control;</text>
                </clause> 
<clause id="H3812D21EAB6E4D5D8934675ACF6F5308">
                  <enum>(iii)</enum>
                  <text>the distribution of a prescription drug product for emergency medical reasons including a public health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health Service Act</cato:entity-ref>, except that a drug shortage not caused by a public health emergency shall not constitute an emergency medical reason;</text>
                </clause> 
<clause id="H4AB9A24B6243445F95C4C1B3026474FF">
                  <enum>(iv)</enum>
                  <text>the dispensing of a prescription drug product pursuant to a valid prescription executed in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>;</text>
                </clause> 
<clause id="H60C8687CB03F41DBA723CB952B3E93BD">
                  <enum>(v)</enum>
                  <text>the distribution of prescription drug product samples by a manufacturer or a licensed wholesale distributor in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">section 503(d)</cato:entity-ref>;</text>
                </clause> 
<clause id="H9663C79D8393405097516A745C6DF6BC">
                  <enum>(vi)</enum>
                  <text>the distribution of blood or blood components intended for transfusion;</text>
                </clause> 
<clause id="H509661EA22844BFCA5E95CD54951A76C">
                  <enum>(vii)</enum>
                  <text>the distribution of minimal quantities of prescription drug product by a licensed retail pharmacy to a licensed practitioner for office use;</text>
                </clause> 
<clause id="H4C94356844014836B212937B3EF83D13">
                  <enum>(viii)</enum>
                  <text>the distribution of a prescription drug product by a charitable organization to a nonprofit affiliate of the organization to the extent otherwise permitted by law;</text>
                </clause> 
<clause id="H1FA425D96E424CA394D18E13925ADF87">
                  <enum>(ix)</enum>
                  <text>the distribution of a prescription drug product pursuant to the sale or merger of a pharmacy or pharmacies or a wholesale distributor or wholesale distributors, except that any records required to be maintained for the prescription drug product shall be transferred to the new owner of the pharmacy or pharmacies or wholesale distributor or wholesale distributors;</text>
                </clause> 
<clause id="H58FE0A8B53C24E3A9F21CFA16F341E84">
                  <enum>(x)</enum>
                  <text>the dispensing of a prescription drug product approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b">section 512(b)</cato:entity-ref>;</text>
                </clause> 
<clause commented="no" id="H89125B1925404B58818F5CCF3A97EC1B">
                  <enum>(xi)</enum>
                  <text>the transfer of prescription drug products to or from any facility that is licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3100">Nuclear Regulatory Commission</cato:entity-ref> or by a State pursuant to an agreement with such Commission under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Atomic Energy Act of 1954/s:274">section 274 of the Atomic Energy Act of 1954</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/2021">
                      <cato:entity-ref entity-type="uscode" value="usc/42/2021">42 U.S.C. 2021</cato:entity-ref>
                    </external-xref>)</cato:entity>;</text>
                </clause> 
<clause commented="no" display-inline="no-display-inline" id="H00224B611AAC4B738B332250DA4C85EE">
                  <enum>(xii)</enum>
                  <text>the distribution of a combination product that consists of—</text> 
<subclause commented="no" id="H61A926CE5E9649CEA755DE239995F212">
                    <enum>(I)</enum>
                    <text>a product comprised of two or more components that are each a drug, biological product, or device and that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</text>
                  </subclause> 
<subclause commented="no" id="H1ED89FBD02434293B48D7700A8BAF69A">
                    <enum>(II)</enum>
                    <text>two or more separate products packaged together in a single package or as a unit and comprised of a drug and device or a device and biological product; or</text>
                  </subclause> 
<subclause commented="no" id="H4E93605BA5FD41D2BA2AEF9E4BE8A991">
                    <enum>(III)</enum>
                    <text>two or more finished devices plus one or more drug or biological products which are packaged together in a medical convenience kit described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:B/cl:xiii" proposed="true">clause (xiii)</cato:entity-ref>;</text>
                  </subclause>
                </clause> 
<clause id="H7146893B06FA4B8E87BBA9805312A546">
                  <enum>(xiii)</enum>
                  <text>the distribution of a medical convenience kit which is a collection of finished products (consisting of devices or drugs) assembled in kit form strictly for the convenience of the purchaser or user if—</text> 
<subclause id="H9C6B0082657F457F92EA066AB62F4C86">
                    <enum>(I)</enum>
                    <text>the medical convenience kit is assembled in an establishment that is registered with the Food and Drug Administration as a medical device manufacturer;</text>
                  </subclause> 
<subclause id="H4581DA7FAF734D8093F9E52F87C93E33">
                    <enum>(II)</enum>
                    <text>the person who manufacturers the medical convenience kit purchased the prescription drug product directly from the manufacturer or from a wholesale distributor that purchased the prescription drug product directly from the manufacturer;</text>
                  </subclause> 
<subclause id="H1F62E0E82563463FB8BFDC7FF6561E12">
                    <enum>(III)</enum>
                    <text>the person who manufacturers the medical convenience kit does not alter the primary container or label of the prescription drug product as purchased from the manufacturer or wholesale distributor;</text>
                  </subclause> 
<subclause id="HB4395CA467414E36B0943ECFFFC0F24B">
                    <enum>(IV)</enum>
                    <text>the medical convenience kit does not contain a controlled substance (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102">section 102 of the Controlled Substances Act</cato:entity-ref>); and</text>
                  </subclause> 
<subclause id="HCE8D07043EF04A91ABE43806C0DC4675">
                    <enum>(V)</enum>
                    <text>the prescription drug products contained in the medical convenience kit are—</text> 
<item id="H7BFBE53262A44CCB89ECEE75A668CEDD">
                      <enum>(aa)</enum>
                      <text>intravenous solutions intended for the replenishment of fluids and electrolytes;</text>
                    </item> 
<item id="H70F210BD6A334EA1BA73F859DAD57FF4">
                      <enum>(bb)</enum>
                      <text>drugs intended to maintain the equilibrium of water and minerals in the body;</text>
                    </item> 
<item id="H7FA0475DE9944CE7A1DAD3EAA5D73D0A">
                      <enum>(cc)</enum>
                      <text>drugs intended for irrigation or reconstitution;</text>
                    </item> 
<item id="HB1370ED09D3D4EBBAD970826802F4803">
                      <enum>(dd)</enum>
                      <text>anesthetics;</text>
                    </item> 
<item id="HF8743A580ABE4617935CDD580E5760B2">
                      <enum>(ee)</enum>
                      <text>anticoagulants;</text>
                    </item> 
<item id="H79334FF2311E41F1B661EF574E7C5B25">
                      <enum>(ff)</enum>
                      <text>vasopressors; or</text>
                    </item> 
<item id="H99B3FF60D6394F0888C5994CB5C88F9A">
                      <enum>(gg)</enum>
                      <text>sympathicomimetics;</text>
                    </item>
                  </subclause>
                </clause> 
<clause id="H05E4733BFB114BA688DC73495AE11758">
                  <enum>(xiv)</enum>
                  <text>the distribution of an intravenous prescription drug product that, by its formulation, is intended for the replenishment of fluids and electrolytes (such as sodium, chloride, and potassium) or calories (such as dextrose and amino acids);</text>
                </clause> 
<clause id="H91E93E6D67D8412AABB3C19810C4766D">
                  <enum>(xv)</enum>
                  <text>the distribution of an intravenous prescription drug product used to maintain the equilibrium of water and minerals in the body, such as dialysis solutions;</text>
                </clause> 
<clause id="HC4BE4F09267C400DA7171D594D7EAB26">
                  <enum>(xvi)</enum>
                  <text>the distribution of a prescription drug product that is intended for irrigation or reconstitution, or sterile water, whether intended for such purposes or for injection;</text>
                </clause> 
<clause id="H14CD42AB892D43DBA23D38357345C0BB">
                  <enum>(xvii)</enum>
                  <text>the distribution of compressed medical gas; or </text>
                </clause> 
<clause id="HD3E12E2C5E1040938628884EF3C70B7E">
                  <enum>(xviii)</enum> 
<subclause id="HCB7BC931E4F94E3495BCB05BB8FC4256" display-inline="yes-display-inline">
                    <enum>(I)</enum>
                    <text display-inline="yes-display-inline">the distribution of a product by a dispenser, or a wholesale distributor acting at the direction of the dispenser, to a repackager registered under section 510 for the purpose of repackaging the drug for use by that dispenser or another health care entity that is under the dispenser’s ownership or control, so long as the dispenser retains ownership of the prescription drug product; and</text>
                  </subclause> 
<subclause id="H6AD6782CD0364088984AB91CF0093A19" indent="up1">
                    <enum>(II)</enum>
                    <text display-inline="yes-display-inline">
                      <italic/>the saleable or nonsaleable return by such repackager of such prescription drug product.</text>
                  </subclause>
                </clause>
              </subparagraph> 
<subparagraph id="H9CD98777B38F46F192DFC7D507AF433E">
                <enum>(C)</enum>
                <header>Compressed medical gas</header>
                <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:B/cl:xvii" proposed="true">subparagraph (B)(xvii)</cato:entity-ref>, the term <term>compressed medical gas</term> means any substance in its gaseous or cryogenic liquid form that meets medical purity standards and has application in a medical or homecare environment, including oxygen and nitrous oxide.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="HA0D3458CD5F449FEA61E78291D0542F7">
              <enum>(22)</enum>
              <header>Transaction history</header>
              <text>The term <term>transaction history</term> means a statement that—</text> 
<subparagraph id="HDED64FC6D3FC4A858570774259A26454">
                <enum>(A)</enum>
                <text>includes the transaction information for each transaction conducted with respect to a prescription drug product beginning with the manufacturer or initial purchase distributor; and</text>
              </subparagraph> 
<subparagraph id="H0805F4770C794072B5527F0DB9856251">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">is in paper or electronic form.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H1B5D1B0D94EE4B18B4C3E91C21CFEFAC">
              <enum>(23)</enum>
              <header>Transaction information</header>
              <text>The term <term>transaction information</term> means—</text> 
<subparagraph id="H06E54C97649D4823B206D50F1461300F">
                <enum>(A)</enum>
                <text>the proprietary or established name or names of the prescription drug product;</text>
              </subparagraph> 
<subparagraph id="HBA7A9D82AF12486F9A202869E7260148">
                <enum>(B)</enum>
                <text>the strength and dosage form of the prescription drug product;</text>
              </subparagraph> 
<subparagraph id="H5846E301B16241019BC6384BE29CEC52">
                <enum>(C)</enum>
                <text>the National Drug Code number of the prescription drug product;</text>
              </subparagraph> 
<subparagraph id="HC71D85028D194315BF948C6CDA7A62A7">
                <enum>(D)</enum>
                <text>the container size;</text>
              </subparagraph> 
<subparagraph id="HF82427A76BC54F5696A445525AC8D18A">
                <enum>(E)</enum>
                <text>the number of containers;</text>
              </subparagraph> 
<subparagraph id="HD9910241DB9E4A088B326442FECF1C7D">
                <enum>(F)</enum>
                <text>the lot number of the prescription drug product;</text>
              </subparagraph> 
<subparagraph id="HA1E350E139784FA0A2CFBEC2D81CDC6A">
                <enum>(G)</enum>
                <text>the date of the transaction;</text>
              </subparagraph> 
<subparagraph id="H7E0CA573322748F1837EE8A47B67346A">
                <enum>(H)</enum>
                <text>the business name and address of the person from whom ownership is being transferred; and</text>
              </subparagraph> 
<subparagraph id="H88A141D5938C4875AA6B475C149BA595">
                <enum>(I)</enum>
                <text>the business name and address of the person to whom ownership is being transferred.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H08897E7CAB1D4C9191E3D09D950ECB5C">
              <enum>(24)</enum>
              <header>Transaction statement</header>
              <text>The <quote>transaction statement</quote> is a statement, which states that the manufacturer, repackager, wholesale distributor, third-party logistics provider, or dispenser transferring ownership in a transaction—</text> 
<subparagraph id="H1DBC1E133E664B808046C221F0DF1DEE">
                <enum>(A)</enum>
                <text>is authorized;</text>
              </subparagraph> 
<subparagraph id="H272C5E4570C34E199BC70F8736323E43">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">received transaction information and a transaction statement as required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref> from the prior owner of the prescription drug product;</text>
              </subparagraph> 
<subparagraph id="H3A12828D4EE9416EB1E197364D689B69">
                <enum>(C)</enum>
                <text>did not knowingly and intentionally ship an illegitimate prescription drug product;</text>
              </subparagraph> 
<subparagraph id="H0ACE3DB0F6A4425DB32E760240592E2A">
                <enum>(D)</enum>
                <text>did not knowingly and intentionally provide false transaction information; and</text>
              </subparagraph> 
<subparagraph id="HB4DAF1DF9FFC48D09D3B16C92DA5CDF1">
                <enum>(E)</enum>
                <text>did not knowingly and intentionally alter the transaction history.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H3703977A871E496E8F92DAE504B47E35">
              <enum>(25)</enum>
              <header>Verification and verify</header>
              <text>The terms <term>verification</term> and <term>verify</term>—</text> 
<subparagraph id="HA4FA706617C24BF282E90731270E380D">
                <enum>(A)</enum>
                <text>mean determining whether the prescription drug product identifier affixed to, or imprinted upon, a package or homogeneous case of the prescription drug product corresponds to the standardized numerical identifier or lot number, and expiration date assigned to the prescription drug product by the manufacturer or the repackager, as applicable; and</text>
              </subparagraph> 
<subparagraph id="HBFB5B46B214B464E85A96EB2F714490B">
                <enum>(B)</enum>
                <text>include making the determination under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:25/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> using human-readable or machine-readable methods.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="HEB076240BEF24866BBBBAECFD1B14487">
              <enum>(26)</enum>
              <header>Wholesale distributor</header>
              <text display-inline="yes-display-inline">The term <term>wholesale distributor</term>—</text> 
<subparagraph id="HB8C8DA192F58404C9D99B743763CB988">
                <enum>(A)</enum>
                <text>means a person engaged in wholesale distribution (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>); and</text>
              </subparagraph> 
<subparagraph id="HC9C51D239FFD46BD8F461D92F9DD6636">
                <enum>(B)</enum>
                <text>excludes—</text> 
<clause id="H967B61DA5624426D8EA202ABCC6C3EFA">
                  <enum>(i)</enum>
                  <text>a manufacturer, a co-licensed partner of a manufacturer, or a third-party logistics provider, or a dispenser who does not engage in such wholesale distribution;</text>
                </clause> 
<clause id="H9290D5D294DA46278353E50D7EC07765">
                  <enum>(ii)</enum>
                  <text>a repackager engaged in such wholesale distribution; or</text>
                </clause> 
<clause id="HA4AC99FB1AF84932BB43B1D7B19A1CFB">
                  <enum>(iii)</enum>
                  <text display-inline="yes-display-inline">the distribution of prescription drug product or an offer to distribute prescription drug product by an authorized repackager that has taken ownership or possession of the prescription drug product and repacked the prescription drug product in accordance with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e" proposed="true">section 582(e)</cato:entity-ref>.</text>
                </clause>
              </subparagraph>
            </paragraph>
          </section> 
<section id="H71C0501CD08441F58A2F8ED2B3A380FF">
            <enum>582.</enum>
            <header>Requirements</header> 
<subsection id="HE5DD0DBF7B30471A800C9EB480AE1312">
              <enum>(a)</enum>
              <header>In general</header> 
<paragraph id="HB4511372352E416FAABCF0881BBB7527">
                <enum>(1)</enum>
                <header>Compliance required</header>
                <text>An entity that is a manufacturer, repackager, wholesale distributor, third-party logistics provider, or dispenser shall comply with the requirements of this section. If an entity meets the definition of more than one of the entities referred to in the preceding sentence, such entity shall comply with all applicable requirements of this section, but shall not be required to comply with duplicative requirements.</text>
              </paragraph> 
<paragraph id="H81BE17D8886F446AB083F94C61319045">
                <enum>(2)</enum>
                <header>Standards</header>
                <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, in consultation with other appropriate Federal officials, manufacturers, repackagers, wholesale distributors, third-party logistics providers, and dispensers, establish, by regulation, standards for the exchange of transaction history and transaction statement (in paper or electronic form) for purposes of complying with this section. The standards established under this paragraph shall be in accordance with a form developed by a widely recognized international standards development organization. In establishing such standards, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consider the feasibility of establishing standardized documentation to be used by all members of the pharmaceutical distribution supply chain to convey the transaction history and transaction statement to the subsequent owner of a prescription drug product. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish such standards not later than 180 days after the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>.</text>
              </paragraph> 
<paragraph id="HF444F6EBF2CE464D9D8A448DE6A15BD9">
                <enum>(3)</enum>
                <header>Waivers, exceptions, and exemptions</header>
                <text>Not later than one year after the date of the enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">
                    <short-title>Safeguarding America’s Pharmaceuticals Act of 2013</short-title>
                  </cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall promulgate a regulation to—</text> 
<subparagraph id="H36B93CD4AC5144E981260C2BD8D4934A">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">establish a process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may grant, at the request of an authorized manufacturer, repackager, wholesale distributor, or dispenser, a waiver from any of the requirements of this section—</text> 
<clause id="HD5746C213E044CBE8BFDD14CC9A7F960">
                    <enum>(i)</enum>
                    <text>if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such requirements would result in an undue economic hardship; or</text>
                  </clause> 
<clause id="H17D03CD0E8BF497E99739D1B35580AEC">
                    <enum>(ii)</enum>
                    <text>for emergency medical reasons, including a public health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health Service Act</cato:entity-ref>;</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H1989095CE6E64C229BBC8C86A36F5065">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">establish a process, with respect to the prescription drug product identifier requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:2" proposed="true">paragraph (2) of subsections (b)</cato:entity-ref>, (c), (d), and (e) through which—</text> 
<clause id="H22DC61CA89614179B7341D45495D5C50">
                    <enum>(i)</enum>
                    <text>a manufacturer or repackager may request a waiver with respect to prescription drug products that are packaged in a container too small or otherwise unable to accommodate a label with sufficient space to bear the information required for compliance with such requirement; and</text>
                  </clause> 
<clause id="HA0AF4DAEA5FC4E71B9E592468ADC9E89">
                    <enum>(ii)</enum>
                    <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines whether to waive such requirement; and</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H0DA8356B06964AC181E569C23F27F3D3">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">establish a process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may add the prescription drug products or transactions that are exempt from the requirements of this section.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="H8BC7F3EDFD5B4B9F97FCFD993923FEAA">
                <enum>(4)</enum>
                <header>Grandfathered persons and prescription drug products</header> 
<subparagraph id="HC96234D47BAD483CA81A22FECC88077C">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text display-inline="yes-display-inline">Not later than one year after the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify, by regulation, whether and under what circumstances the prescription drug product identifier requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:2" proposed="true">paragraph (2) of subsections (b)</cato:entity-ref>, (c), (d), and (e) shall apply to a prescription drug product that is in the supply chain or in a manufacturer’s inventory on the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>.</text>
                </subparagraph> 
<subparagraph commented="no" id="H0A84DF4BB1624799B241A0F8A24283D8">
                  <enum>(B)</enum>
                  <header>Third-party logistics provider licenses</header>
                  <text display-inline="yes-display-inline">Until the date that is 1 year after the effective date of the third-party logistics provider licensing requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref>, a third-party logistics provider shall be considered <quote>licensed</quote> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:6/sp:B" proposed="true">section 581(6)(B)</cato:entity-ref> unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has made a finding that the third-party logistics provider does not utilize good handling and distribution practices and publishes notice thereof.</text>
                </subparagraph> 
<subparagraph commented="no" id="H7088891DC9BB4CA697969CD37AE2D1DF">
                  <enum>(C)</enum>
                  <header>Label changes</header>
                  <text>Changes made to package labels solely to incorporate the prescription drug product identifier may be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the annual report of an establishment, in accordance with section 314.70(d) of chapter 21, Code of Federal Regulations (or any successor regulation).</text>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="HDE7726CCB1BB44FD82CCFAA996DA9DB4">
              <enum>(b)</enum>
              <header>Manufacturer requirements</header> 
<paragraph id="H93C771D1EF174F99B642A3B29DE8983F">
                <enum>(1)</enum>
                <header>Prescription drug product tracing</header> 
<subparagraph id="H8A1C7550803248C1AFD138176BD6E63F">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text>Beginning not later than January 1, 2015, a manufacturer shall—</text> 
<clause id="HED01CD3765004C198DEFFB240E084564">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">prior to, or at the time of, each transaction in which such manufacturer transfers ownership of a prescription drug product—</text>
<subclause id="H8B2DE1ED708A4006A92138F7F069BB9E">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">until the date than is 5 years after the date of the enactment of the <short-title>
                          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                        </short-title>, provide the subsequent owner with the transaction history and a transaction statement in a single document in paper or electronic form; and</text>
                    </subclause>
<subclause id="H170303AAA8A541AD8943BFADC38F2167">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">on or after such date, provide the subsequent owner with the transaction history and a transaction statement in electronic form; and</text>
                    </subclause>
                  </clause> 
<clause id="HBBB348AEA5654B19AB8A3FF3E91948BE">
                    <enum>(ii)</enum>
                    <text>maintain the transaction information for each such transaction for not less than 3 years after the date of the transaction.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HF54FDE6A40EF490181DCCA77AA2B547B">
                  <enum>(B)</enum>
                  <header>Requests for information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate Federal or State official, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product, a manufacturer shall, not later than 2 business days after receiving the request or in such reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other official, the applicable transaction history and transaction statement for the prescription drug product.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="HF4F5F23916F94EBF96EEDE4ED471BC0D">
                <enum>(2)</enum>
                <header>Prescription drug product identifier</header>
                <text display-inline="yes-display-inline">Beginning not later than 5 years after the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a manufacturer shall affix or imprint a prescription drug product identifier on each package and homogenous case of a prescription drug product intended to be introduced in a transaction. Such manufacturer shall maintain the information in the prescription drug product identifier for such prescription drug product for not less than 3 years after the date of the transaction.</text>
              </paragraph> 
<paragraph id="HDFEE5BBF894643E7AB18123662BB8A05">
                <enum>(3)</enum>
                <header>Authorized trading partners</header>
                <text>Beginning not later than January 1, 2015, a manufacturer shall ensure that each of its trading partners is authorized.</text>
              </paragraph> 
<paragraph id="H78D2FA7615B549A4AEE8E2A487AECD8F">
                <enum>(4)</enum>
                <header>List of authorized distributors of record</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015, each manufacturer of a prescription drug shall—</text> 
<subparagraph id="H2E98A5775D3F4E709F41A0CBE8E5070B">
                  <enum>(A)</enum>
                  <text>maintain a list of the authorized distributors of record of such drug at the corporate offices of such manufacturer;</text>
                </subparagraph> 
<subparagraph id="HBCAD7C8DDFC7491999DE85F24A387D16">
                  <enum>(B)</enum>
                  <text>make such list publicly available, including placement on the Internet Website of such manufacturer; and</text>
                </subparagraph> 
<subparagraph id="H26216042A65543BEA7A98F35353DD888">
                  <enum>(C)</enum>
                  <text>update such list not less than once per quarter.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="HC7C7757A73BB471B80000F06545A7E2A">
                <enum>(5)</enum>
                <header>Verification</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015, a manufacturer shall implement systems and processes to enable the manufacturer to comply with the following requirements:</text> 
<subparagraph id="H9C7CE5A6AE244D1CBCD0D48AAF6B9A2B">
                  <enum>(A)</enum>
                  <header>Suspect prescription drug product</header> 
<clause id="H5267D7FE68AA467F89A90E4EDFC7E643">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon making a determination that a prescription drug product in the possession or control of the manufacturer is a suspect prescription drug product, or upon receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control of a manufacturer is a suspect prescription drug product, a manufacturer shall promptly conduct an investigation in coordination with trading partners, as applicable, to determine whether the prescription drug product is an illegitimate prescription drug product. Beginning not later than 5 years after the date of the enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                      </short-title>, such investigation shall include—</text> 
<subclause id="H73BCD5B9F02144FA8A3C5B3CD96BD8F8">
                      <enum>(I)</enum>
                      <text>verifying the prescription drug product at the package level;</text>
                    </subclause> 
<subclause id="H4DC45F51291643CC95D927F2D7D45508">
                      <enum>(II)</enum>
                      <text>validating any applicable transaction history in the possession of the manufacturer; and</text>
                    </subclause> 
<subclause id="H7CE59224D88A407DB37F58345484426E">
                      <enum>(III)</enum>
                      <text>otherwise investigating to determine whether the prescription drug product is an illegitimate prescription drug product.</text>
                    </subclause>
                  </clause> 
<clause id="H3209BD6108AB4F6684CBF97F2142009E">
                    <enum>(ii)</enum>
                    <header>Cleared prescription drug product</header>
                    <text>If the manufacturer determines that a suspect prescription drug product is not an illegitimate prescription drug product, the manufacturer shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination and such prescription drug product may be further distributed.</text>
                  </clause> 
<clause id="H13926D4AF3544462B30BCD205C67BACE">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A manufacturer shall keep records of its investigation of a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HFEE04915BC7F40DA93E79B2D47C05FCD">
                  <enum>(B)</enum>
                  <header>Illegitimate prescription drug product</header> 
<clause id="H3A0AC0B4F28B4D3EB086F057489BAD15">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon determining that a prescription drug product in the possession or control of a manufacturer is an illegitimate prescription drug product, the manufacturer shall—</text> 
<subclause id="H5B864482D7094A259A4EF07859850F0C">
                      <enum>(I)</enum>
                      <text>quarantine such prescription drug product from prescription drug product intended for distribution; and</text>
                    </subclause> 
<subclause id="HB591B58ABACD4CDEBBB0611718A9D5F5">
                      <enum>(II)</enum>
                      <text>provide for the disposition of the illegitimate prescription drug product.</text>
                    </subclause>
                  </clause> 
<clause id="H11D401AD74134C939189575D0FB1C51F">
                    <enum>(ii)</enum>
                    <header>Trading partner</header>
                    <text display-inline="yes-display-inline">Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the manufacturer shall take reasonable steps to assist a trading partner to provide for the disposition of the illegitimate prescription drug product.</text>
                  </clause> 
<clause id="H74DD4DB6C81D46E0AD8473CCB80129E4">
                    <enum>(iii)</enum>
                    <header>Making a notification</header>
                    <text>Upon determining that a prescription drug product in the possession or control of the manufacturer is an illegitimate prescription drug product, the manufacturer shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner notification is appropriate.</text>
                  </clause> 
<clause id="H065DBCDE555844879D8104C8CB3DEA82">
                    <enum>(iv)</enum>
                    <header>Responding to a notification</header>
                    <text>Upon the receipt of a notification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a determination has been made that a prescription drug product is an illegitimate prescription drug product, a manufacturer shall—</text> 
<subclause id="H9902DAC7E75747FE9DEB69E01DB341A2">
                      <enum>(I)</enum>
                      <text>identify all illegitimate prescription drug products that are subject to such notification and in the possession or control of the manufacturer, including any prescription drug product that is subsequently received; and</text>
                    </subclause> 
<subclause id="H187A546A521745F98503BA68E27FF1D1">
                      <enum>(II)</enum>
                      <text>perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:b/p:5/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
                    </subclause>
                  </clause> 
<clause commented="no" id="H449B818942F046B5B905E3DE0821825E">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A manufacturer shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H6EC3B184EE634C9780A2E9411CCC8799">
                  <enum>(C)</enum>
                  <header>Electronic database</header>
                  <text>A manufacturer may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to respond to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a manufacturer of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.</text>
                </subparagraph> 
<subparagraph id="HB3D5E95603784639A6083D6781081521">
                  <enum>(D)</enum>
                  <header>Returned prescription drug product</header>
                  <text>Beginning not later than 5 years after the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, upon receipt of a returned prescription drug product that the manufacturer intends to further distribute, before further distributing such prescription drug product, the manufacturer shall—</text> 
<clause id="HFAB09BF035B74E8888FD990323DD3C2E">
                    <enum>(i)</enum>
                    <text>verify the prescription drug product identifier for each sealed homogeneous case of such prescription drug product; or</text>
                  </clause> 
<clause id="HE0EFA59D6BE94955B09F5CE3C4353368">
                    <enum>(ii)</enum>
                    <text>if such prescription drug product is not in a sealed homogeneous case, verify the prescription drug product identifier on each package.</text>
                  </clause>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="HDAEEBC04648647F5A79759AC17916FFF">
              <enum>(c)</enum>
              <header>Wholesale distributor requirements</header> 
<paragraph id="HE38C23020EEA433F9EAC86ECC619F9C9">
                <enum>(1)</enum>
                <header>Prescription drug product tracing</header> 
<subparagraph id="H8A5B5A45B3794076A236AB5880409FAF">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text>Beginning not later than April 1, 2015, a wholesale distributor shall—</text> 
<clause id="HF358BE81A6D845719F95998BDDCD4B97">
                    <enum>(i)</enum>
                    <text>not accept ownership of a prescription drug product unless the previous owner prior to, or at the time of, the transaction provides the applicable transaction history and a transaction statement for the prescription drug product;</text>
                  </clause> 
<clause id="HA3AB0A01A93842D087E867C90C87AD78">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:iv" proposed="true">clause (iv)</cato:entity-ref>, prior to, or at the time of, each transaction in which the wholesale distributor transfers ownership of a prescription drug product—</text> 
<subclause id="H9F4611BCA8224B6AA1B29371717AE866">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">in the case that the wholesale distributor purchased the prescription drug product directly from the manufacturer, the exclusive distributor of the manufacturer, or a repackager that purchased directly from the manufacturer, provide the subsequent owner with transaction history and a transaction statement for the prescription drug product—</text>
<item id="H6821245E25954DDB80FE873CB5F78BC2">
                        <enum>(aa)</enum>
                        <text display-inline="yes-display-inline">if the subsequent owner is a dispenser, on a single document in paper or electronic form; or</text>
                      </item>
<item id="HF8CA5F9F804D4B86AD6A610B06FD9D8B">
                        <enum>(bb)</enum>
                        <text display-inline="yes-display-inline">if the subsequent owner is a wholesale distributor, through any combination of self-generated paper, electronic data, or manufacturer-provided information on the product package;</text>
                      </item>
                    </subclause> 
<subclause id="HC8D3B59222C046829384B9143E1A11E6">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">in the case that the wholesale distributor did not purchase the prescription drug product as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii/scl:I" proposed="true">subclause (I)</cato:entity-ref>—</text>
<item id="H62505F72B2544699B6D41C8B0480248E">
                        <enum>(aa)</enum>
                        <text display-inline="yes-display-inline">provide the subsequent owner with the transaction history and a transaction statement beginning with the wholesale distributor that did so purchase the prescription drug product in paper or electronic form; or</text>
                      </item>
<item id="H2B28F1967B5D41F98662506F47BAF3FA">
                        <enum>(bb)</enum>
                        <text>pursuant to a written agreement between the wholesale distributor and a dispenser, maintain the transaction history and transaction statement on behalf of the dispenser and if requested by the dispenser, provide the transaction history and transaction statement to the dispenser in paper or electronic form in a timely manner so as to permit the dispenser to comply with requests pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:D" proposed="true">subsection (d)(1)(D)</cato:entity-ref>;</text>
                      </item>
                    </subclause>
                  </clause> 
<clause id="HA6521AD4D72048378AA540E580261AB4">
                    <enum>(iii)</enum>
                    <text display-inline="yes-display-inline">maintain the transaction information for each transaction described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> for not less than 3 years after the transaction; and</text>
                  </clause>
<clause id="H7BF566D6348D45CB9689B835B6703E11">
                    <enum>(iv)</enum>
                    <text display-inline="yes-display-inline">on or after the date that is 5 years after the date of the enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                      </short-title>, provide the transaction history and transaction statement in electronic form.</text>
                  </clause>
                </subparagraph>
<subparagraph id="HBB3A96972475436CA0ECE7C6FC632661" display-inline="no-display-inline">
                  <enum>(B)</enum>
                  <header>Inclusion of lot number in transaction history</header>
                  <text display-inline="yes-display-inline">Until the date that is 5 years after the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, the transaction history provided by a wholesale distributer under this paragraph shall not be required to include the lot number of the product or the initial date of the transaction from the manufacturer (as such terms are used in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:23/sp:F" proposed="true">subparagraphs (F)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:23/sp:G" proposed="true">(G) of section 581(23)</cato:entity-ref>).</text>
                </subparagraph> 
<subparagraph commented="no" id="H84C7E0A4CA76498091F76AF38D4422AA">
                  <enum>(C)</enum>
                  <header>Returns exception</header> 
<clause commented="no" id="H8F2FCF6D1ED844FB8DAF180D00611567">
                    <enum>(i)</enum>
                    <header>Saleable returns</header>
                    <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, a wholesale distributor may—</text> 
<subclause commented="no" id="H828D0DEB84934F69BBB865FDF9E4603D">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">accept returned prescription drug product without a transaction history from a dispenser or repackager; and</text>
                    </subclause> 
<subclause commented="no" id="HAAB26EA0A4C74FA3B2FB10550206CB95">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">distribute such returned prescription drug product with a transaction history that begins with the wholesale distributor that so accepted the returned product.</text>
                    </subclause>
                  </clause> 
<clause commented="no" id="HEADFF6C093E5441A95B17F9B12360E9C">
                    <enum>(ii)</enum>
                    <header>Nonsaleable returns</header>
                    <text>A wholesale distributor may return a nonsaleable prescription drug to the manufacturer or repackager, to the wholesale distributor from whom such prescription drug was purchased, or to a person acting on behalf of such a person, including a returns processor, without providing the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:c/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HDF3DF31209EE4079BD617579E244611E">
                  <enum>(D)</enum>
                  <header>Requests for information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate Federal or State official, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product a wholesale distributor shall, not later than 2 business days after receiving the request or in such other reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide the applicable transaction history and transaction statements for the prescription drug product.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="HE3EF1DD7E9CD46F5BF7B0208D38FD0FD">
                <enum>(2)</enum>
                <header>Prescription drug product identifier</header>
                <text>Beginning not later than 7 years after the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a wholesale distributor may engage in transactions involving a prescription drug product only if such prescription drug product is encoded with a prescription drug product identifier, except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref>.</text>
              </paragraph> 
<paragraph id="HAD789185BC49470CB6B35D95508FC403">
                <enum>(3)</enum>
                <header>Authorized trading partners</header>
                <text>Beginning not later than January 1, 2015, a wholesale distributor shall ensure that each of its trading partners is authorized.</text>
              </paragraph> 
<paragraph id="HBDDCD16D027348378785DD05CDB35FE5">
                <enum>(4)</enum>
                <header>Verification</header>
                <text>Beginning not later than April 1, 2015, a wholesale distributor shall implement systems to enable the wholesale distributor to comply with the following requirements:</text> 
<subparagraph id="H784BF951686E45D588D1305728974362">
                  <enum>(A)</enum>
                  <header>Suspect prescription drug product</header> 
<clause id="H6D7001079351457192D4946F1FDD2451">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon making a determination that a prescription drug product in the possession or control of the wholesale distributor is a suspect prescription drug product, or upon receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control of a wholesale distributor is a suspect prescription drug product, a wholesale distributor shall promptly conduct an investigation to determine whether the prescription drug product is an illegitimate prescription drug product. Beginning not later than 7 years after the date of the enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                      </short-title>, such investigation shall include—</text> 
<subclause id="H10D43B9C05914D0E8EBA5DAB78C0A6BE">
                      <enum>(I)</enum>
                      <text>verifying a package of the prescription drug product;</text>
                    </subclause> 
<subclause id="H146C4091C2834C0398724A2E01EC98BD">
                      <enum>(II)</enum>
                      <text>validating any applicable transaction history in the possession of the wholesale distributor; and</text>
                    </subclause> 
<subclause id="H09623E5EBC8A4CDD92D3EF99D40C7799">
                      <enum>(III)</enum>
                      <text>otherwise investigating to determine whether the prescription drug product is an illegitimate prescription drug product.</text>
                    </subclause>
                  </clause> 
<clause id="HC129878935094863838B8A9DFC48C100">
                    <enum>(ii)</enum>
                    <header>Cleared prescription drug product</header>
                    <text>If the wholesale distributor determines that a suspect prescription drug product is not an illegitimate prescription drug product, the wholesale distributor shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination and such prescription drug product may be further distributed.</text>
                  </clause> 
<clause id="H449DB66E74D942299F932E5A3A5F0A2E">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A wholesale distributor shall keep records of its investigation of a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H73AC154FC5334BCF926A9629A59B15F5">
                  <enum>(B)</enum>
                  <header>Illegitimate prescription drug product</header> 
<clause id="H8907E731AE1E4184A9D95353885F8177">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a wholesale distributor is an illegitimate prescription drug product, the wholesale distributor shall—</text> 
<subclause id="HA5B2554D0D2D4790BFA8A8876DC2D41B">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">quarantine such prescription drug product within the possession or control of the wholesale distributor from prescription drug product intended for distribution; and</text>
                    </subclause> 
<subclause id="HF451136C8F514D2B8046663FA9E61E49">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">provide for the disposition of the illegitimate prescription drug product within the possession or control of the wholesale distributor.</text>
                    </subclause>
                  </clause> 
<clause id="HA48F0BA8C2B24747A0ACD8EB622E708D">
                    <enum>(ii)</enum>
                    <header>Trading partner</header>
                    <text display-inline="yes-display-inline">Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the wholesale distributor shall take reasonable steps to assist a trading partner to provide for the disposition of the illegitimate prescription drug product.</text>
                  </clause> 
<clause id="H52BAB69781D5433B9C934BCB1A02FC3D">
                    <enum>(iii)</enum>
                    <header>Making a notification</header>
                    <text>Upon determining that a prescription drug product in the possession or control of the wholesale distributor is an illegitimate prescription drug product, the wholesale distributor shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner notification is appropriate.</text>
                  </clause> 
<clause id="H4041C98EA56E4BFE883331AF38E4EF42">
                    <enum>(iv)</enum>
                    <header>Responding to a notification</header>
                    <text>Upon the receipt of a notification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a determination has been made that a prescription drug product is an illegitimate prescription drug product, a wholesale distributor shall—</text> 
<subclause id="HA332EF64D0614B05959AF1631D4E2788">
                      <enum>(I)</enum>
                      <text>identify all illegitimate prescription drug products subject to such notification that are in the possession or control of the wholesale distributor, including any such prescription drug product that is subsequently received; and</text>
                    </subclause> 
<subclause id="HDC9D33DFBD33451386B94391C91B2441">
                      <enum>(II)</enum>
                      <text>perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:582/ss:c/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
                    </subclause>
                  </clause> 
<clause commented="no" id="HFEF39694BD74404996DA2A0A1F53118D">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A wholesale distributor shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H8270EFEEDBDA4683B3B81305C4B8DB4B">
                  <enum>(C)</enum>
                  <header>Electronic database</header>
                  <text>A wholesale distributor may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to respond to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a wholesale distributor of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.</text>
                </subparagraph> 
<subparagraph id="H34D4603E354B4D9280956AF490D2622C">
                  <enum>(D)</enum>
                  <header>Returned prescription drug product</header>
                  <text>Beginning not later than 7 years after the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, upon receipt of a returned prescription drug product that the wholesale distributor intends to further distribute, before further distributing such prescription drug product, the wholesale distributor shall—</text> 
<clause id="HF2730D19AA6C4A34B02B5F5768B54E48">
                    <enum>(i)</enum>
                    <text>verify the prescription drug product identifier for each sealed homogeneous case of such prescription drug product; or</text>
                  </clause> 
<clause id="H3A1911AEF4D447809C53798B59F2C3E5">
                    <enum>(ii)</enum>
                    <text>if such prescription drug product is not in a sealed homogeneous case, verify the prescription drug product identifier on each package.</text>
                  </clause>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="HA153C3C9985A4B50BDD4502AF7C0F399">
              <enum>(d)</enum>
              <header>Dispenser requirements</header> 
<paragraph id="H32FCCAE5320E418086FDEE8A3B8CF9E6">
                <enum>(1)</enum>
                <header>Prescription drug product tracing</header> 
<subparagraph id="H51FB9B18CE7C41539F7316CF87097681">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text>Beginning not later than July 1, 2015, a dispenser—</text> 
<clause id="H9B651CE1EBFA4A33BFD9F8986B7EE6EA">
                    <enum>(i)</enum>
                    <text>shall not accept ownership of a prescription drug product, unless the previous owner prior to, or at the time of, the transaction, provides transaction history and a transaction statement;</text>
                  </clause> 
<clause id="HBB7D26F096DD419C95261F3C7A33A9D0">
                    <enum>(ii)</enum>
                    <text>prior to, or at the time of, each transaction in which the dispenser transfers ownership of a prescription drug product (but not including dispensing to a patient or returns) shall provide the subsequent owner with transaction history and a transaction statement for the prescription drug product, except that the requirements of this clause shall not apply to sales by a dispenser to another dispenser to fulfill a specific patient need; and</text>
                  </clause> 
<clause id="H96D51716ABDD4560911E75005666D37D">
                    <enum>(iii)</enum>
                    <text>shall maintain transaction information for a period of not less than 3 years after the date of the transaction.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HC216D00AF07D4C2897084DFC88A86652">
                  <enum>(B)</enum>
                  <header>Agreements with third parties</header>
                  <text>A dispenser may enter into a written agreement with a third party, including an authorized wholesale distributor, under which the third party confidentially maintains the transaction information required to be maintained under this subsection on behalf of the dispenser. If a dispenser enters into such an agreement, the dispenser shall maintain a copy of the written agreement.</text>
                </subparagraph> 
<subparagraph commented="no" id="H856A3AE9951348EDB7DDD8E91133CC2D">
                  <enum>(C)</enum>
                  <header>Returns exception</header> 
<clause commented="no" id="HA016D38FFA824631963CCF9203207799">
                    <enum>(i)</enum>
                    <header>Saleable returns</header>
                    <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a dispenser may return prescription drug product to the trading partner from which the dispenser obtained the prescription drug product without providing the information required under such subparagraph.</text>
                  </clause> 
<clause commented="no" id="H798794507CAD463E9ED49560926A6172">
                    <enum>(ii)</enum>
                    <header>Nonsaleable returns</header>
                    <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a dispenser may return a nonsaleable prescription drug to the manufacturer or repackager, to the wholesale distributor from whom such prescription drug was purchased, to a returns processor, or to a person acting on behalf of such persons without providing the information required under such subparagraph.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HAD5C9737C2FB41E3A321AB2FED353FD4">
                  <enum>(D)</enum>
                  <header>Requests for information</header>
                  <text display-inline="yes-display-inline">Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate Federal or State official, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product—</text>
<clause id="HCA5F383880374128835B9544705C7D39">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">a dispenser shall not later than 2 business days after receiving the request or in another such reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide the applicable transaction history and transaction statement which the dispenser received from the previous owner; </text>
                  </clause>
<clause id="HF8D4DA5A4ABE422787DF1AE47C0DCD1D">
                    <enum>(ii)</enum>
                    <text>the information provided by the dispenser under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:1/sp:D/cl:i" proposed="true">clause (i)</cato:entity-ref> is not required to include the lot number of the product, the initial date of the transaction, or the initial date of the shipment from the manufacturer unless such information was provided electronically by the previous owner, manufacturer, or wholesale distributor to the dispenser; and</text>
                  </clause>
<clause id="H358B2751142B4FC1834DD6FE97AA9AAF">
                    <enum>(iii)</enum>
                    <text>a dispenser may respond to the request by providing the paper documentation received from the previous owner or by providing electronic information.</text>
                  </clause>
                </subparagraph>
              </paragraph> 
<paragraph id="H4E6D92BCDFB94A64B7F4323192580975">
                <enum>(2)</enum>
                <header>Prescription drug product identifier</header>
                <text>Beginning not later than 8 years after the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a dispenser may engage in transactions involving a prescription drug product only if such prescription drug product is encoded with a prescription drug product identifier, except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref>.</text>
              </paragraph> 
<paragraph id="HBCB883318C394B89A05E33AC53CAC3B9">
                <enum>(3)</enum>
                <header>Authorized trading partners</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015, a dispenser shall ensure that each of its trading partners is authorized.</text>
              </paragraph> 
<paragraph id="H62E6FC0E53174730B42ABAA0E6A664B3">
                <enum>(4)</enum>
                <header>Verification</header>
                <text>Beginning not later than January 1, 2015, a dispenser shall implement systems to enable the dispenser to comply with the following requirements:</text> 
<subparagraph id="H8D0755AC5BCA4BE8B951E9EF69A38B93">
                  <enum>(A)</enum>
                  <header>Suspect prescription drug product</header> 
<clause id="HE578663D21AC417D8E798EEF74A99522">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon making a determination that a prescription drug product in the possession or control of the dispenser is a suspect prescription drug product, or upon receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control of a dispenser is a suspect prescription drug product, a dispenser shall promptly conduct an investigation to determine whether the prescription drug product is an illegitimate prescription drug product. Such investigation shall include—</text> 
<subclause id="HB595F116F48744C18FBB508B30780D90">
                      <enum>(I)</enum>
                      <text>verifying whether the lot number of a suspect prescription drug product corresponds with the lot number for such prescription drug product;</text>
                    </subclause> 
<subclause id="H01BEE980B2084D7E8DB1ACFE958C5B52">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">beginning 8 years after the date of the enactment of the <short-title>
                          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                        </short-title>, verifying that the product identifier of at least 3 packages or 10 percent of such suspect prescription drug product, whichever is greater, or all packages, if there are fewer than 3, corresponds with the prescription drug product identifier for such product;</text>
                    </subclause> 
<subclause id="HEB72C2071C08468B9E4A9445847F99F5">
                      <enum>(III)</enum>
                      <text>validating any applicable transaction history in the possession of the dispenser; and</text>
                    </subclause> 
<subclause id="H92C1306157044E5EBF036D0BEBBD326B">
                      <enum>(IV)</enum>
                      <text>otherwise investigating to determine whether the prescription drug product is an illegitimate prescription drug product.</text>
                    </subclause>
                  </clause> 
<clause id="H762B7EA1F4B440ABB794494F55E075A3">
                    <enum>(ii)</enum>
                    <header>Cleared prescription drug product</header>
                    <text>If the dispenser makes the determination that a suspect prescription drug product is not an illegitimate prescription drug product, the dispenser shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination and such prescription drug product may be further dispensed.</text>
                  </clause> 
<clause id="HFE846892ABE446509B3337D715F65878">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A dispenser shall keep records of its investigation of a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H908DD621667547879A086DF889CEF0F6">
                  <enum>(B)</enum>
                  <header>Illegitimate prescription drug product</header> 
<clause id="H6DD028F6F237425E8217B55957241949">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text display-inline="yes-display-inline">Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a dispenser is an illegitimate prescription drug product, the dispenser shall—</text> 
<subclause id="H366CC3D5BB9944F6A6CA4D907E35831B">
                      <enum>(I)</enum>
                      <text>quarantine such prescription drug product within the possession or control of the dispenser from prescription drug product intended for distribution; and</text>
                    </subclause> 
<subclause id="HC0F7E17FAB8C4D30B15BAC024AE6CD59">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">provide for the disposition of the illegitimate prescription drug product within the possession or control of the dispenser.</text>
                    </subclause>
                  </clause> 
<clause id="HF3BD549E0DD3401BB5822FEEC19DEC67">
                    <enum>(ii)</enum>
                    <header>Trading partners</header>
                    <text display-inline="yes-display-inline">Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the dispenser shall take reasonable steps to assist a trading partner to provide for the disposition of the illegitimate prescription drug product.</text>
                  </clause> 
<clause id="HFC2E466CB0A34F348F0DB0CD2FBBD629">
                    <enum>(iii)</enum>
                    <header>Making a notification</header>
                    <text>Upon determining that a prescription drug product in the possession or control of the dispenser is an illegitimate prescription drug product, the dispenser shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner notification is appropriate.</text>
                  </clause> 
<clause id="HC7B6543B08364A05A05DE62A2240FDFE">
                    <enum>(iv)</enum>
                    <header>Responding to a notification</header>
                    <text>Upon the receipt of a notification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a determination has been made that a prescription drug product is an illegitimate prescription drug product, a dispenser shall—</text> 
<subclause id="H72CD49771CFF454488A85BC2182F505A">
                      <enum>(I)</enum>
                      <text>identify all illegitimate prescription drug products that are subject to such notification and in the possession or control of the dispenser, including any such prescription drug product that is subsequently received; and</text>
                    </subclause> 
<subclause id="H0C271878843F4428AFE3D08691D1049E">
                      <enum>(II)</enum>
                      <text>perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:d/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
                    </subclause>
                  </clause> 
<clause commented="no" id="HA5A85A171F074615A9537B841D4CC655">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A dispenser shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H8C3FDAA0DA58416FA562E4B3B555E3FA">
                  <enum>(C)</enum>
                  <header>Electronic database</header>
                  <text>A dispenser may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to enable responding to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a dispenser of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.</text>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="H0C2943620FA249BC8ECF8CB91FAE8C91">
              <enum>(e)</enum>
              <header>Repackager requirements</header> 
<paragraph id="HEF3462AF1E884E03B584AA51FE0980D3">
                <enum>(1)</enum>
                <header>Prescription drug product tracing</header> 
<subparagraph id="H22EDE739E9C64A30AD824720EFBB5F45">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text display-inline="yes-display-inline">Beginning not later than April 1, 2015, with respect to a prescription drug product received by a repackager from a wholesale distributor, and beginning not later than January 1, 2015, with respect to any other prescription drug product, a repackager shall—</text> 
<clause id="HD5A7ADB6CB4C4FECB26C90C5ED49BE5D">
                    <enum>(i)</enum>
                    <text>not accept ownership of a prescription drug product unless the previous owner, prior to, or at the time of, the transaction, provides transaction history and a transaction statement for the prescription drug product;</text>
                  </clause> 
<clause id="H582642AED2874A728EC9141B9AF43938">
                    <enum>(ii)</enum>
                    <text>prior to, or at the time of, each transaction in which the repackager transfers ownership of a prescription drug product, provide the subsequent owner with transaction history and a transaction statement;</text>
                  </clause> 
<clause id="H6B20B3ED522D4C91BB9D7A19682A2073">
                    <enum>(iii)</enum>
                    <text>maintain the transaction information for each transaction described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> for not less than 3 years after the transaction; and</text>
                  </clause> 
<clause id="H39B94589F0D54A4F8F1BA609A3FB585F">
                    <enum>(iv)</enum>
                    <text>maintain records that allow the repackager to associate the prescription drug product identifier the repackager affixes or imprints with the prescription drug product identifier assigned by the original manufacturer of the prescription drug product.</text>
                  </clause>
                </subparagraph>
<subparagraph id="HE5416AB86C4A48B680A229887DA5709A" commented="no">
                  <enum>(B)</enum>
                  <header>Returns exception</header>
                  <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a repackager may return prescription drug product to the trading partner from whom the repackager obtained the prescription drug product without providing the information required under such subparagraph.</text> </subparagraph> 
<subparagraph id="HEC38E021BAF641AEA9C6D99CC8ADB73E">
                  <enum>(C)</enum>
                  <header>Requests for information</header>
                  <text>Upon a request by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> or other appropriate Federal or State official, in the event of a recall or for the purpose of investigating a suspect prescription drug product or an illegitimate prescription drug product, a repackager shall, not later than 2 business days after receiving the request or in such other reasonable time as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide the applicable transaction history and transaction statement for the prescription drug product.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="H3EF4D88D5E124F4DABF96E10B8B6C1B0">
                <enum>(2)</enum>
                <header>Prescription drug product identifier</header>
                <text>Beginning not later than 6 years after the date of the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                  </short-title>, a repackager—</text> 
<subparagraph id="H4F58E37772B643B988324D06CFC873BD">
                  <enum>(A)</enum>
                  <text>shall affix or imprint a prescription drug product identifier to each package and homogenous case of prescription drug product intended to be introduced in a transaction;</text>
                </subparagraph> 
<subparagraph id="HFB8B45501A9F47B8A5D0DD3A77B9CCC5">
                  <enum>(B)</enum>
                  <text>shall maintain the prescription drug product identifier for such prescription drug product for not less than 3 years after the date of the transaction; and</text>
                </subparagraph> 
<subparagraph id="HF77109894C344F0FA0CBCFA3C060436D">
                  <enum>(C)</enum>
                  <text>may engage in transactions involving a prescription drug product only if such prescription drug product is encoded with a prescription drug product identifier except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref>.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="HE3736BCC659C45BDABA1D92C7AE78BA8">
                <enum>(3)</enum>
                <header>Authorized trading partners</header>
                <text display-inline="yes-display-inline">Beginning on January 1, 2015, a repackager shall ensure that each of its trading partners is authorized.</text>
              </paragraph> 
<paragraph id="H73F64C1ADFBE44569BF7602778012737">
                <enum>(4)</enum>
                <header>Verification</header>
                <text>Beginning not later than January 1, 2015, a repackager shall implement systems to enable the repackager to comply with the following requirements:</text> 
<subparagraph id="H4D2D1FD823A9436FB7690D7EA4353A28">
                  <enum>(A)</enum>
                  <header>Suspect prescription drug product</header> 
<clause id="HFAC2B70F2F164772B99DF84FB1D9F41E">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon making a determination that a prescription drug product in the possession or control of the repackager is a suspect prescription drug product, or upon receiving a request for verification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a prescription drug product within the possession or control of a repackager is a suspect prescription drug product, a repackager shall promptly conduct an investigation to determine whether the prescription drug product is an illegitimate prescription drug product, including—</text> 
<subclause id="H856D07D71D64418986A5C3BF2046DB6A">
                      <enum>(I)</enum>
                      <text>beginning not later than 6 years after the date of the enactment of the <short-title>
                          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                        </short-title>, verifying the prescription drug product at the package level;</text>
                    </subclause> 
<subclause id="H4040B486060C4D8E89C49E93D8A044AA">
                      <enum>(II)</enum>
                      <text>validating any applicable transaction information in the possession of the repackager; and</text>
                    </subclause> 
<subclause id="HD794CF852E3B4F60890B51FEDF3F5E30">
                      <enum>(III)</enum>
                      <text>otherwise investigating to determine whether the prescription drug product is an illegitimate prescription drug product.</text>
                    </subclause>
                  </clause> 
<clause id="H633CB9A56AF542E7AE3D9F159762ACD5">
                    <enum>(ii)</enum>
                    <header>Cleared prescription drug product</header>
                    <text>If the repackager determines that a suspect prescription drug product is not an illegitimate prescription drug product, the repackager shall promptly notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination and such prescription drug product may be further distributed.</text>
                  </clause> 
<clause id="HE821108487D740ED9551957BCE7772DB">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A repackager shall keep records of its investigation of a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H5003E64CE7EF4462B27AA1A7E7341AFB">
                  <enum>(B)</enum>
                  <header>Illegitimate prescription drug product</header> 
<clause id="HCBFF09E89C074B708D53BA6EBCBF8051">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text display-inline="yes-display-inline">Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a repackager is an illegitimate prescription drug product, the repackager shall—</text> 
<subclause id="H6EC0E17F248C4DF69E1B2620389B28C3">
                      <enum>(I)</enum>
                      <text>quarantine such prescription drug product within the possession or control of the repackager from prescription drug product intended for distribution; and</text>
                    </subclause> 
<subclause id="H28384594BAF9447199CE9DFA50479194">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">provide for the disposition of the illegitimate prescription drug product within the possession or control of the repackager.</text>
                    </subclause>
                  </clause> 
<clause id="H4F02397AAD2E4604A9E4F1347F2A148C">
                    <enum>(ii)</enum>
                    <header>Trading partner</header>
                    <text display-inline="yes-display-inline">Upon determining that a prescription drug product in the possession or control of a trading partner is an illegitimate prescription drug product, the repackagers shall take reasonable steps to assist the trading partner to provide for the disposition of the illegitimate prescription drug product.</text>
                  </clause> 
<clause id="HAB6CCF7CCFE74B54B09B141202F7EFF0">
                    <enum>(iii)</enum>
                    <header>Making a notification</header>
                    <text>Upon determining that a prescription drug product in the possession or control of the repackager is an illegitimate prescription drug product, the repackager shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such determination not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner notification is appropriate.</text>
                  </clause> 
<clause id="HA7EF30840DD84A91846E3D3D008F0945">
                    <enum>(iv)</enum>
                    <header>Responding to a notification</header>
                    <text>Upon the receipt of a notification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that a determination has been made that a prescription drug product is an illegitimate prescription drug product, a repackager shall—</text> 
<subclause id="H619953DCC0884C1DA575AA1E7BAE5F8E">
                      <enum>(I)</enum>
                      <text>identify all illegitimate prescription drug products that are subject to such notification and in the possession or control of the repackager, including any such prescription drug product that is subsequently received; and</text>
                    </subclause> 
<subclause id="H5B481B60F8214336A983BF8D189E4308">
                      <enum>(II)</enum>
                      <text>perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
                    </subclause>
                  </clause> 
<clause id="H867E4AC6CAC0422BBC60FBE1D8F6211C">
                    <enum>(v)</enum>
                    <header>Records</header>
                    <text>A repackager shall keep records of the disposition of an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HD5C672EF774840C68CE17C25205F11C4">
                  <enum>(C)</enum>
                  <header>Electronic database</header>
                  <text>A repackager may satisfy the requirements of this paragraph through the use of a secure electronic database developed and operated by the manufacturer or another entity. The owner of such database shall establish the requirements and processes to respond to requests and may provide for data access to other members of the pharmaceutical distribution supply chain, as appropriate. The development and operation of such a database shall not relieve a repackager of the requirement under this paragraph to respond to a verification request submitted by means other than a secure electronic database.</text>
                </subparagraph> 
<subparagraph id="H1493FA1A5F194377AD3799FE7D8DABD0">
                  <enum>(D)</enum>
                  <header>Returned prescription drug product</header>
                  <text>Beginning not later than 6 years after the date of the enactment of the <short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                    </short-title>, upon receipt of a returned prescription drug product that the repackager intends to further distribute, before further distributing such prescription drug product, the repackager shall—</text> 
<clause id="HB7473D4C0A134CB383D0740B982329B4">
                    <enum>(i)</enum>
                    <text>verify the prescription drug product identifier for each sealed homogeneous case of such prescription drug product; or</text>
                  </clause> 
<clause id="H87BFD3DE3DD7476C8CF2F77F5FE7B0CB">
                    <enum>(ii)</enum>
                    <text>if such prescription drug product is not in a sealed homogeneous case, verify the prescription drug product identifier on each package.</text>
                  </clause>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="HE65A3D27465E42D8BDF91DB9A429F05A">
              <enum>(f)</enum>
              <header>Third-Party logistics provider requirements</header> 
<paragraph id="H5EBBC36A3C9E4AFD958EC16B75F1F949">
                <enum>(1)</enum>
                <header>Authorized trading partners</header>
                <text display-inline="yes-display-inline">Beginning on January 1, 2015, a third-party logistics provider shall ensure that each of its trading partners is authorized.</text>
              </paragraph> 
<paragraph id="H3CF26870DE7649AB84EF0F1AE9215E9D">
                <enum>(2)</enum>
                <header>Verification</header>
                <text display-inline="yes-display-inline">Beginning not later than January 1, 2015, a third-party logistics provider shall implement systems to enable the third-party logistics provider to comply with the following requirements:</text> 
<subparagraph id="H8E29888EA5D24206A23DB86722255A99">
                  <enum>(A)</enum>
                  <header>Suspect prescription drug product</header> 
<clause id="H8DCEEBF2ADC8479CB6F80A0CA4B58BED">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text>Upon making a determination that a prescription drug product in the possession or control of a third-party logistics provider is a suspect prescription drug product, a third-party logistics provider shall promptly notify the owner of such prescription drug product of the need to conduct an investigation to determine whether the prescription drug product is an illegitimate prescription drug product.</text>
                  </clause> 
<clause id="HA4655CCE62904E299206170AD6D6C636">
                    <enum>(ii)</enum>
                    <header>Cleared prescription drug product</header>
                    <text>If the owner of the prescription drug product notifies the third-party logistics provider of the determination that a suspect prescription drug product is not an illegitimate prescription drug product, such prescription drug product may be further distributed.</text>
                  </clause> 
<clause id="H0AC5C31633224E548B8B4AC8DA6E0EFF">
                    <enum>(iii)</enum>
                    <header>Records</header>
                    <text>A third-party logistics provider shall keep records of the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> with respect to a suspect prescription drug product for not less than 3 years after the conclusion of the investigation.</text>
                  </clause>
                </subparagraph> 
<subparagraph id="H40926CC15D7240F1AD9572748B3C331D">
                  <enum>(B)</enum>
                  <header>Illegitimate prescription drug product</header> 
<clause id="H88A36ABC7B6741B3964F10DDB077900A">
                    <enum>(i)</enum>
                    <header>In general</header>
                    <text display-inline="yes-display-inline">Upon receiving notice that a manufacturer of a prescription drug product has determined that a prescription drug product in the possession or control of a third-party logistics provider is an illegitimate prescription drug product, the third-party logistics provider shall—</text> 
<subclause id="HB23862E670534510A4843A735CE99F63">
                      <enum>(I)</enum>
                      <text>quarantine such prescription drug product within the possession or control of the third-party logistics provider from prescription drug product intended for distribution;</text>
                    </subclause> 
<subclause id="H9DE4E8DE18D146A8B1D06735CEA9965A">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">promptly notify the owner of such prescription drug product of the need to provide for the disposition of such prescription drug product; and</text>
                    </subclause> 
<subclause id="HA6FACD1B3C7B414E8E55A6BF511D3DE9">
                      <enum>(III)</enum>
                      <text display-inline="yes-display-inline">promptly transfer possession of the prescription drug product to the owner of such prescription drug product to provide for the disposition of the prescription drug product.</text>
                    </subclause>
                  </clause> 
<clause id="H24142A9FE35D4529B893F52F9987D213">
                    <enum>(ii)</enum>
                    <header>Making a notification</header>
                    <text>Upon determining that a prescription drug product in the possession or control of the third-party logistics provider is an illegitimate prescription drug product, the third-party logistics provider shall notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 24 hours after making such determination. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine whether additional trading partner notification is appropriate.</text>
                  </clause> 
<clause id="H7553D7F144BA496BAA001C9649675DE9">
                    <enum>(iii)</enum>
                    <header>Responding to a notification</header>
                    <text>Upon the receipt of a notification from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, a third-party logistics provider shall—</text> 
<subclause id="H8C882B13B9694EC28C849DD8FE942A7C">
                      <enum>(I)</enum>
                      <text>identify all illegitimate prescription drug products subject to such notification that are in the possession or control of the third-party logistics provider, including any such prescription drug product that is subsequently received; and</text>
                    </subclause> 
<subclause id="HF7641161D7544598A39F3E5011F878C0">
                      <enum>(II)</enum>
                      <text>perform the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
                    </subclause>
                  </clause> 
<clause id="H2A169D9509A04D408FD9BC673C3B50C8">
                    <enum>(iv)</enum>
                    <header>Records</header>
                    <text>A third-party logistics provider shall keep records of the activities described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:B/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:f/p:2/sp:B/cl:ii" proposed="true">(ii)</cato:entity-ref> with respect to an illegitimate prescription drug product for not less than 3 years after the conclusion of the disposition.</text>
                  </clause>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="H732781C64B09483A9DC3A8C20FA9A437">
              <enum>(g)</enum>
              <header>Drop shipments</header>
              <text>This section does not apply to any entity, notwithstanding its status as a wholesale distributor or repackager, or other status that is not involved in the physical handling, distribution, or storage of a prescription drug product. For purposes of this subsection, facilitating the distribution of a prescription drug product by providing various administrative services, including processing of orders and payments, shall not, by itself, be construed as being involved in the handling, distribution, or storage of a prescription drug product.</text>
            </subsection>
          </section>
        </subchapter>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section> 
<section id="H5FB5AF949194479DA7725A68B6E54A64">
      <enum>3.</enum>
      <header>Enhanced drug distribution security</header> 
<subsection id="HB96FCCD917AE4099B0DDC040C97573CC">
        <enum>(a)</enum>
        <header>Pilot projects</header> 
<paragraph id="HE538F40C45044BBD9B712B71D385C613">
          <enum>(1)</enum>
          <header>In general</header>
          <text>Not later than 2 years after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish one or more pilot projects in coordination with manufacturers, repackagers, wholesale distributors, third-party logistics providers, and dispensers to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain.</text>
        </paragraph> 
<paragraph id="H2BED1DC7D53248F9B4F0326CB5FB91E2">
          <enum>(2)</enum>
          <header>Content</header> 
<subparagraph id="HAA0CEBEA1AE14394BFBB1F0C8715B100">
            <enum>(A)</enum>
            <header>In general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall ensure that the pilot projects under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> collectively—</text> 
<clause id="HFB187C8567D4426FAACF6780260C859C">
              <enum>(i)</enum>
              <text>reflect the diversity of the pharmaceutical distribution supply chain; and</text>
            </clause> 
<clause id="H73C6354160554234A5CFE9BAED1DFCC7">
              <enum>(ii)</enum>
              <text>include participants representative of every sector within the pharmaceutical distribution supply chain, including participants representative of small businesses.</text>
            </clause>
          </subparagraph> 
<subparagraph id="H38FFE554726445E9AD4AF31F722BFA4F">
            <enum>(B)</enum>
            <header>Project design</header>
            <text>The pilot projects shall be designed to—</text> 
<clause id="H86C23104F18E4258A80DD918E92B8A4E">
              <enum>(i)</enum>
              <text>utilize the prescription drug product identifier for tracing of a prescription drug product, which utilization may include—</text> 
<subclause id="H8184B8047F3D46CF849EC76752DBD716">
                <enum>(I)</enum>
                <text>verification of the prescription drug product identifier of a prescription drug product; and</text>
              </subclause> 
<subclause id="H626D4F5E21C54EC3BD442EDEA2AE684D">
                <enum>(II)</enum>
                <text>the use of aggregation and inference;</text>
              </subclause>
            </clause> 
<clause id="H8C8271BF97644D4E9E83B3F4E2432295">
              <enum>(ii)</enum>
              <text>improve the technical capabilities of each sector within the pharmaceutical supply chain to comply with systems and processes needed to utilize the prescription drug product identifiers to enhance tracing of a prescription drug product; and</text>
            </clause> 
<clause id="HA3725BB9DE3149FBB98BC9435BE65B11">
              <enum>(iii)</enum>
              <text>conduct such other activities as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines appropriate to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain.</text>
            </clause>
          </subparagraph>
        </paragraph>
      </subsection> 
<subsection id="H86E840CDA2354306B2400138BD140054">
        <enum>(b)</enum>
        <header>Public meetings</header> 
<paragraph id="H1197A207D30B4C88886835CDDD31DF5D">
          <enum>(1)</enum>
          <header>In general</header>
          <text>Not later than 6 months after the date of the enactment of this Act, and at least every 6 months thereafter until the submission of the report required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:e/p:2" proposed="true">subsection (e)(2)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold a public meeting to enhance the safety and security of the pharmaceutical distribution supply chain. In conducting such meetings, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall take all measures reasonable and practicable to ensure the protection of confidential commercial information and trade secrets.</text>
        </paragraph> 
<paragraph id="HC19AF6A0EF9141A790B32D183B0E7A52">
          <enum>(2)</enum>
          <header>Content</header>
          <text>In conducting meetings under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall seek to address, in at least one such meeting, each of the following topics:</text> 
<subparagraph id="HDBC1B29B5F594F44BF86336E49E47003">
            <enum>(A)</enum>
            <text>Best practices in each of the sectors within the pharmaceutical distribution supply chain to implement the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>.</text>
          </subparagraph> 
<subparagraph id="HEFEF94279A634E5FBF27F031DDF67870">
            <enum>(B)</enum>
            <text>The costs and benefits of implementation of such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>, including the impact on each pharmaceutical distribution supply chain sector and on public health.</text>
          </subparagraph> 
<subparagraph commented="no" id="H53DAA987FDB34752A17A03B0E617E9A4">
            <enum>(C)</enum>
            <text>Whether additional electronic traceability requirements, including tracing of prescription drug product at the package level, are feasible, cost effective, overly burdensome on small businesses, and needed to protect public health.</text>
          </subparagraph> 
<subparagraph id="HD2CA9957D9A74CF2B2F5372E2B288EF9">
            <enum>(D)</enum>
            <text>The systems and processes needed to utilize the prescription drug product identifiers to enhance tracing of prescription drug product at the package level, including allowing for verification, aggregation, and inference by each sector within the pharmaceutical distribution supply chain for cases, pallets, totes, and other containers of aggregated prescription drug product as necessary.</text>
          </subparagraph> 
<subparagraph id="HEAF63E2898FC4E8BA8131E0ADB9C3124">
            <enum>(E)</enum>
            <text>The technical capabilities and legal authorities, if any, needed to establish an electronic system that provides for enhanced tracing of prescription drug product at the package level.</text>
          </subparagraph> 
<subparagraph id="H95B949CD40B54613B47279EA6B0350DA">
            <enum>(F)</enum>
            <text>The impact that the requirements, systems, processes, capabilities, and legal authorities referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b/p:2/sp:C" proposed="true">subparagraphs (C)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b/p:2/sp:D" proposed="true">(D)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b/p:2/sp:E" proposed="true">(E)</cato:entity-ref> would have on patient safety, the drug supply, cost and regulatory burden, the timeliness of patient access to prescription drugs, and small businesses.</text>
          </subparagraph>
        </paragraph>
      </subsection> 
<subsection id="HB77BDCA06BAC4FEC8798B9A83ED0F757">
        <enum>(c)</enum>
        <header>Study of the pharmaceutical distribution supply chain</header> 
<paragraph id="H63766FE7537E46BA97931F7B1AD1A693">
          <enum>(1)</enum>
          <header>In general</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of the United States</cato:entity-ref> shall conduct a study to examine implementation of the requirements established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">subchapter H of chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, in order to inform the regulations promulgated under this section.</text>
        </paragraph> 
<paragraph id="H1E9702061DCF4E07895E02AA6556B44C">
          <enum>(2)</enum>
          <header>Consideration</header>
          <text>In conducting the study under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General</cato:entity-ref> shall provide for stakeholder input and shall consider the following:</text> 
<subparagraph id="HBC1F4DA1E0FF452B91F64574FA6FB5EC">
            <enum>(A)</enum>
            <text>The implementation of the requirements established under such subchapter H with respect to—</text> 
<clause id="H8823AC205A7B46ACBDE100E8696024CD">
              <enum>(i)</enum>
              <text>the ability of the health care system collectively to maintain patient access to medicines;</text>
            </clause> 
<clause id="H92F47935D595403AB45A531934A99482">
              <enum>(ii)</enum>
              <text>the scalability of such requirements, including with respect to prescription drug product lines; and</text>
            </clause> 
<clause id="H91F88350090A41F88FFB4261DE0E6F6D">
              <enum>(iii)</enum>
              <text>the capability of different sectors within the pharmaceutical distribution supply chain, including small businesses, to affix and utilize the prescription drug product identifier.</text>
            </clause>
          </subparagraph> 
<subparagraph id="HD421A26B033948638448B7F41F7056C5">
            <enum>(B)</enum>
            <text>The need for additional legal authorities and activities to address additional gaps in the pharmaceutical distribution supply chain, if any, after the implementation of the requirements established under such subchapter H with respect to—</text> 
<clause id="H30EB56FBD9BB4ADB97D5B13B09D4587F">
              <enum>(i)</enum>
              <text display-inline="yes-display-inline">the systems and processes needed to enhance tracing of prescription drug product at the package level, including the use and evaluation of verification, aggregation, and inference by each sector within the pharmaceutical distribution supply chain as necessary;</text>
            </clause> 
<clause id="HEB5E545DC0E340BA90792DABE2D67E8E">
              <enum>(ii)</enum>
              <text>the impact, feasibility, and cost effectiveness that additional requirements pursuant to this section would have on each pharmaceutical distribution supply chain sector and the public health; and</text>
            </clause> 
<clause id="H47284733784140BDBF42998C2981D486">
              <enum>(iii)</enum>
              <text>the systems and processes needed to enhance interoperability among trading partners.</text>
            </clause>
          </subparagraph> 
<subparagraph id="H83EC20FB632F415DA2996EFBED2FB43C">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">Risks to the security and privacy of data collected, maintained, or exchanged pursuant to the requirements established under such subchapter H.</text>
          </subparagraph>
        </paragraph>
      </subsection> 
<subsection id="HC27B8C0AF3354CE4AAE8786AE5D7C780">
        <enum>(d)</enum>
        <header>Small dispensers</header> 
<paragraph id="H60630EC99461437C8737FEF9A2CF6C10">
          <enum>(1)</enum>
          <header>In general</header>
          <text display-inline="yes-display-inline">Not later than 10 years after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall enter into a contract with a private, independent consulting firm with relevant expertise to conduct a technology and software study on the feasibility of dispensers that have 25 or fewer full-time employees conducting interoperable, electronic tracing of prescription drug products at the package level.</text>
        </paragraph> 
<paragraph id="HD7236D923E4B491D8B82E2836035C1CA">
          <enum>(2)</enum>
          <header>Condition</header>
          <text display-inline="yes-display-inline">As a condition of the award of a contract under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the private independent consulting firm awarded such contract shall agree to consult with dispensers that have 25 or fewer full-time employees when conducting the study under such subparagraph.</text>
        </paragraph> 
<paragraph id="HE88E085E506C4DB1ACEBB660ADE91CBE">
          <enum>(3)</enum>
          <header>Study content</header>
          <text>The study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall assess whether, with respect to conducting interoperable, electronic tracing of prescription drug products at the package level, the necessary hardware and software—</text> 
<subparagraph id="HD955E51856A3430A987BEEC7AB8C1BA0">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">is readily accessible to such dispensers;</text>
          </subparagraph> 
<subparagraph id="H041508962A8D448FBAA810253CBC4A61">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">is not prohibitively expensive to obtain, install, and maintain for such dispensers; and</text>
          </subparagraph> 
<subparagraph id="HA4352AB633EB4A98B1879AC8BD1FE044">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">can be integrated into business practices, such as interoperability with wholesale distributors, for such dispensers.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="H9E36A9BC04CB456B86AA482EE3DE2B48">
          <enum>(4)</enum>
          <header>Publication</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish—</text> 
<subparagraph id="H3061EA004B8F4DA183C391CC053FF2FB">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">the statement of work for the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> for public comment not later than 30 days before commencing the study; and</text>
          </subparagraph> 
<subparagraph id="HA41E1D6054E34872B0C898AC7C1C47B0">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">the final version of such study for public comment not later than 30 days after such study is completed.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="H55F5F911388F446A942DF72F073F9FFA">
          <enum>(5)</enum>
          <header>Report to Congress</header>
          <text display-inline="yes-display-inline">Not later than 30 days after the date on which the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> is completed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and Pensions of the Senate</cato:entity-ref>, a report on the findings of the study and any recommendations to improve the technology and software available to small dispensers for purposes of conducting electronic, interoperable tracing of prescription drug products at the package level.</text>
        </paragraph> 
<paragraph id="H1869118EA1474012A2FC28313558E692">
          <enum>(6)</enum>
          <header>Public meeting</header>
          <text display-inline="yes-display-inline">Not later than 180 days after the date on which the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> is completed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold a public meeting at which members of the public, including stakeholders, may present their views on the study.</text>
        </paragraph>
      </subsection> 
<subsection id="HA6AC662557AC4D8FB1BEFD53EE7E9FE6">
        <enum>(e)</enum>
        <header>Reports</header> 
<paragraph id="H63C67DF554DF42F485228DDFF9D05119">
          <enum>(1)</enum>
          <header>GAO report</header>
          <text>Not later than 12 years after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> a report on the results of the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
        </paragraph> 
<paragraph id="HFDA5BE43F3B34B63B5DE794615EDA25D">
          <enum>(2)</enum>
          <header>FDA report</header>
          <text>Not later than 12 years after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> a report on the results of the pilot program conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref>, taking into consideration—</text> 
<subparagraph id="H7F0BC17F3BBB4FB1AE1ADD91D55F7665">
            <enum>(A)</enum>
            <text>the comments received during the public meetings conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b" proposed="true">subsection (b)</cato:entity-ref>; and</text>
          </subparagraph> 
<subparagraph id="H40A8F3FF4B1A49ED8AD18EDA60186490">
            <enum>(B)</enum>
            <text>the results of the study conducted, and the public comments received during the public meeting held, under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d" proposed="true">subsection (d)</cato:entity-ref>.</text>
          </subparagraph>
        </paragraph>
      </subsection> 
<subsection id="HD429AB2CAD454A6DA5746659B7D4E6C9">
        <enum>(f)</enum>
        <header>Establishment of additional requirements</header> 
<paragraph id="H198D1345260044F6BA334E449F26322B">
          <enum>(1)</enum>
          <header>In general</header>
          <text display-inline="yes-display-inline">Notwithstanding any other provision of this Act, including the amendments made by this Act, not earlier than January 1, 2027, and not later than March 1, 2027, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue proposed regulations that establish additional requirements to prevent a suspect product, illegitimate product, or a product that is counterfeit, stolen, diverted, or otherwise unfit for distribution from entering into or being further distributed in the supply chain, including—</text> 
<subparagraph id="H7B850F325A434F6CB1D480CA61A25AE0">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">requirements related to the use of interoperable electronic systems and technologies for enhanced tracing of prescription drug product at the package level, which may include verification of the prescription drug product identifier of a package of prescription drug product and enhanced verification of saleable returns;</text>
          </subparagraph> 
<subparagraph id="H496B0034930C4B1DA367AD6B9BD430E7">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">requirements related to the use of additional prescription drug product identifiers or prescription drug product identifier technology that meet the standards developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a/p:2" proposed="true">section 582(a)(2) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>;</text>
          </subparagraph> 
<subparagraph id="HD74B24113F5C43739B7D3BF721BBFF14">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">requirements related to the use of aggregation, inference, and other methods, which shall permit the use of aggregation and inference for cases, pallets, totes, and other containers of aggregated prescription drug products by each sector of the pharmaceutical distribution supply chain, if determined to be necessary components of the systems and technologies referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>; and</text>
          </subparagraph> 
<subparagraph id="H36C5D43123904CA0B836E5B82DF1E72B">
            <enum>(D)</enum>
            <text>other data transmission and maintenance requirements and interoperability standards.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="HED1D647314274412AA980F1EF3E85CF1">
          <enum>(2)</enum>
          <header>Flexibility</header>
          <text>The requirements described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall provide for flexibility for a member of the pharmaceutical supply chain, by—</text> 
<subparagraph id="HAB65B8B1F42D40318ED2282E03476D2C">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">with respect to dispensers, allowing a dispenser to enter into a written agreement with a third party, including an authorized wholesale distributor, under which—</text> 
<clause id="H9F24954EE6C54BC0B6CFA0428A39BEBF">
              <enum>(i)</enum>
              <text>the third party confidentially maintains any information required to be maintained under such requirements for the dispenser; and</text>
            </clause> 
<clause id="H662FA244DF554A99A50496F33055340E">
              <enum>(ii)</enum>
              <text>the dispenser maintains a copy of the written agreement and is not relieved of the other obligations of the dispenser under such requirements;</text>
            </clause>
          </subparagraph> 
<subparagraph id="HA4164B13C0A7460ABB7697F4E84F3BF4">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">establishing a process by which an authorized manufacturer, repackager, wholesale distributor, or dispenser may request a waiver from any such requirements if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such requirements would result in an undue economic hardship on the manufacturer, wholesale distributor, or dispenser;</text>
          </subparagraph> 
<subparagraph id="H5524249D83274680A64715B11263C282">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">not requiring the adoption of specific business systems by a member of the pharmaceutical supply chain for the maintenance and transmission of prescription drug product tracing data; and</text>
          </subparagraph> 
<subparagraph id="HAFA778941E904FB38ECEC78F52EAB167">
            <enum>(D)</enum>
            <text display-inline="yes-display-inline">prescribing alternative methods of compliance for small businesses, as specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="H5B694B7806F94278B433316F399162F4">
          <enum>(3)</enum>
          <header>Considerations</header>
          <text>In issuing proposed regulations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consider—</text> 
<subparagraph id="HF654D099A1DE4BD5A4353A3CCF075532">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">the results of, and public comments resulting from, the pilot project conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref>;</text>
          </subparagraph> 
<subparagraph id="H12BD7A3F9E5A4D8585E8C20B5DDCC924">
            <enum>(B)</enum>
            <text>the public meetings held under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:b" proposed="true">subsection (b)</cato:entity-ref> and public comments from such meetings;</text>
          </subparagraph> 
<subparagraph id="HE8238BD34E1844E0A3A29BCBF47E07F8">
            <enum>(C)</enum>
            <text>the studies conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:c" proposed="true">subsections (c)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d" proposed="true">(d)</cato:entity-ref>;</text>
          </subparagraph> 
<subparagraph id="HD02B4A940F68411B8106D4AD327CCBB8">
            <enum>(D)</enum>
            <text>the reports submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:e" proposed="true">subsection (e)</cato:entity-ref>;</text>
          </subparagraph> 
<subparagraph id="HD292921AC9BA45699C887D944ADA2593">
            <enum>(E)</enum>
            <text display-inline="yes-display-inline">the public health benefits of such regulations compared with the cost of compliance with the requirements contained in such regulations, including with respect to entities of varying sizes and capabilities; and</text>
          </subparagraph> 
<subparagraph id="H5E375D4F502248E1936BB410A3944350">
            <enum>(F)</enum>
            <text display-inline="yes-display-inline">the diversity of the pharmaceutical distribution supply chain by providing appropriate flexibility for each sector in the supply chain, including small businesses.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="H94FEE74324534DF7AA8ADB55E9686214">
          <enum>(4)</enum>
          <header>Small business protection</header>
          <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, taking into consideration the study conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:d" proposed="true">paragraph (d)</cato:entity-ref>, shall, if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that the requirements established pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:3/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> would result in an undue economic hardship on small businesses, provide for alternative methods of compliance with any such requirement by small businesses, including—</text> 
<subparagraph id="H02148601A3F64259A5CD7D01E9CA0CC5">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">establishing timelines for such compliance (including compliance by dispensers with 25 or fewer full-time employees) that do not impose undue economic hardship for small businesses, including dispensers with respect to which the study concluded has insufficient hardware and software to conduct interoperable, electronic tracing of prescription drug products at the package level; and</text>
          </subparagraph> 
<subparagraph id="HB0FC1827796A454A950711B11A344F26">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">establishing a process by which a dispenser may request a waiver from any such requirement.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="H0E22D67748AA4E53A3141AA3981D4EAA">
          <enum>(5)</enum>
          <header>Regulations</header>
          <text>In issuing regulations to carry out this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text> 
<subparagraph id="HDAB7DC6447A948928759E3BB3AD31527">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">issue a notice of proposed rulemaking that includes a copy of the proposed rule;</text>
          </subparagraph> 
<subparagraph id="H800084E78928415B92CC32DC59FB26EC">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">provide for a period of not less than 60 days for comments on the proposed rule; and</text>
          </subparagraph> 
<subparagraph id="H5774A93130984D6DB983FBA4F9CF25D4">
            <enum>(C)</enum>
            <text display-inline="yes-display-inline">provide for an effective date of the final rule that is 2 years after the date on which such final rule is published.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="HC850566872794782A846D3E6DA19A565">
          <enum>(6)</enum>
          <header>Sunset</header>
          <text display-inline="yes-display-inline">The requirements regarding the provision and receipt of transaction history and transaction statements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, shall cease to be effective on the date on which the regulations issued under this section are fully implemented.</text>
        </paragraph>
      </subsection> 
<subsection commented="no" id="HA56CCE760C8341C081BA30D732BA2A31">
        <enum>(g)</enum>
        <header>Definitions</header>
        <text display-inline="yes-display-inline">In this section:</text> 
<paragraph commented="no" id="HEBEFAABB50244A4A95A78ED13589D108">
          <enum>(1)</enum>
          <text display-inline="yes-display-inline">The terms defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section 581 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, shall have the same meanings in this section as such terms are given in such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section 581</cato:entity-ref>.</text>
        </paragraph> 
<paragraph commented="no" id="H63E0914BD7DD43CAA332120B9B258166">
          <enum>(2)</enum>
          <text>The term <term>Secretary</term> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref>.</text>
        </paragraph>
      </subsection>
    </section> 
<section id="HC92C03A1E14A4091A405B1E94899365C">
      <enum>4.</enum>
      <header>National standards for wholesale distributors</header> 
<subsection id="H34A4126A76DB4147ACB54A781CDA1F5D">
        <enum>(a)</enum>
        <header>Standards</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
            <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq</cato:entity-ref>.</external-xref>)</cato:entity> is amended—</text> 
<paragraph id="HC601FD2D9BC34767B329D8BD29BA1AA1">
          <enum>(1)</enum>
          <text>in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503">section 503</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
              <cato:entity-ref entity-type="uscode" value="usc/21/353">21 U.S.C. 353</cato:entity-ref>
            </external-xref>)</cato:entity>, by striking <quote>(e)(1)(A)</quote> and all that follows through <quote>(3) For the purposes of this subsection and subsection (d)—</quote> and inserting the following:</text> 
<quoted-block display-inline="no-display-inline" id="H9E526E50F04D48FAA0507A65D72EBC93" style="OLC"> 
<subsection id="H03C9ECF0B3BD46F88135E14C08916F88">
              <enum>(e)</enum>
              <text display-inline="yes-display-inline">For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:d">subsection (d)</cato:entity-ref>—</text>
            </subsection>
            <after-quoted-block>;</after-quoted-block>
          </quoted-block>
        </paragraph> 
<paragraph id="HE099496DB2304201A13ABA0F3F04C8C7">
          <enum>(2)</enum>
          <text display-inline="yes-display-inline">in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e">section 503(e)</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353">
              <cato:entity-ref entity-type="uscode" value="usc/21/353/e">21 U.S.C. 353(e)</cato:entity-ref>
            </external-xref>)</cato:entity>, by redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1/sp:A">subparagraphs (A)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1/sp:B">(B)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:1" proposed="true">paragraphs (1)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:e/p:2" proposed="true">(2)</cato:entity-ref>, respectively; and</text>
        </paragraph> 
<paragraph id="HF6B273569C774AE380548E5012CBF6A4">
          <enum>(3)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">subchapter H</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:2" proposed="true">section 2</cato:entity-ref>, by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H450946E48A9A416B85C0C79DA8450220" style="OLC"> 
<section id="HE583038F09334737A6911184C3A4F265">
              <enum>583.</enum>
              <header>National standards for wholesale distributors</header> 
<subsection commented="no" id="H224E0FCC2F7E4D2B8F021CFBFF6BD54E">
                <enum>(a)</enum>
                <header>Standards</header> 
<paragraph id="HC930AAEE9D3746EA8DAA7DA586B58B6B">
                  <enum>(1)</enum>
                  <header>In general</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, by regulation, standards for the licensing of persons that make wholesale distributions.</text>
                </paragraph> 
<paragraph id="HF193C58F446E4F2791DA9DDA87DF5C3B">
                  <enum>(2)</enum>
                  <header>Requirements</header>
                  <text>The standards under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall, with respect to wholesale distributions, include requirements for—</text> 
<subparagraph id="HFB6D36581CBA40D7A513DC6FCE0EB200">
                    <enum>(A)</enum>
                    <text>the storage and handling of drugs subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>, including facility requirements;</text>
                  </subparagraph> 
<subparagraph id="H89CC9CFD683D4EF9A361E69E73367746">
                    <enum>(B)</enum>
                    <text>the establishment and maintenance of records of the distributions of such drugs;</text>
                  </subparagraph> 
<subparagraph commented="no" id="HF4A1FB8872A941179F12E8A1437898FF">
                    <enum>(C)</enum>
                    <text>the furnishing of a bond or other equivalent means of security in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:3" proposed="true">paragraph (3)</cato:entity-ref>;</text>
                  </subparagraph> 
<subparagraph id="H846138EC6C264FCEB5A3E111D0B00D5E">
                    <enum>(D)</enum>
                    <text>mandatory background checks and fingerprinting of facility managers or designated representatives;</text>
                  </subparagraph> 
<subparagraph id="H9C30B764E63445E08FB84D356E393F11">
                    <enum>(E)</enum>
                    <text>the establishment and implementation of qualifications for key personnel;</text>
                  </subparagraph> 
<subparagraph id="H2B798C9667044F5398D5C9E18409708F">
                    <enum>(F)</enum>
                    <text>the mandatory physical inspection of any facility to be used in wholesale distribution within a reasonable timeframe from the initial application for licensure of the wholesale distributor; and</text>
                  </subparagraph> 
<subparagraph id="H83D8ED4E73A34F8EBDE88F3FA0C588DE">
                    <enum>(G)</enum>
                    <text>in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:5" proposed="true">paragraph (5)</cato:entity-ref>, the prohibition of certain persons from engaging in wholesale distribution.</text>
                  </subparagraph>
                </paragraph> 
<paragraph commented="no" id="H0885F084297049939E2DAC6A586BB74C">
                  <enum>(3)</enum>
                  <header>Bond or other security</header>
                  <text>The requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:2/sp:C" proposed="true">paragraph (2)(C)</cato:entity-ref> shall provide for the following:</text> 
<subparagraph commented="no" id="H15C9ABC3CEC3451D8420EDB40C75D26F">
                    <enum>(A)</enum>
                    <text>An applicant that is not a government-owned-and-operated wholesale distributor, for the issuance or renewal of a wholesale distributor license, shall submit a surety bond of $100,000 or other equivalent means of security acceptable to the applicable licensing authority.</text>
                  </subparagraph> 
<subparagraph commented="no" id="H091F65E123894E5687B38B0787C995E3">
                    <enum>(B)</enum>
                    <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the applicable licensing authority may accept a surety bond of less than $100,000 if the annual gross receipts of the previous tax year for the wholesale distributor is $10,000,000 or less, in which case the surety bond may not be less than $25,000.</text>
                  </subparagraph> 
<subparagraph commented="no" id="H5091B0D9D79249369AAAAD4DEB3B428A">
                    <enum>(C)</enum>
                    <text>If a wholesale distributor can provide evidence that it possesses the required bond in a State, the requirement for a bond in another State is waived.</text>
                  </subparagraph>
                </paragraph> 
<paragraph commented="no" id="HFFEDEBA703004C0D894A2952056DF400">
                  <enum>(4)</enum>
                  <header>Inspections</header>
                  <text>To satisfy the inspection requirement under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:2/sp:F" proposed="true">paragraph (2)(F)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may conduct the inspection, or may accept an inspection by—</text> 
<subparagraph id="H7FFAD74E467F4D0395B537AD8283B165">
                    <enum>(A)</enum>
                    <text>the government of the State in which the facility is located; or</text>
                  </subparagraph> 
<subparagraph id="H9429DB48D7DD4C85BBF472C8F196C2C0">
                    <enum>(B)</enum>
                    <text>a third-party accreditation or inspection service approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
                  </subparagraph>
                </paragraph> 
<paragraph id="H308E93A2BED846F08FE71E59B19CA6A3">
                  <enum>(5)</enum>
                  <header>Prohibited persons</header>
                  <text>The requirements under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a/p:2" proposed="true">paragraph (2)</cato:entity-ref> shall include requirements to prohibit a person from receiving or maintaining licensure for wholesale distribution if the person—</text> 
<subparagraph id="HD0D80457CAF84212A676F80E8577E8C7">
                    <enum>(A)</enum>
                    <text>has been convicted of—</text>
<clause id="HB8BDD7FF15844958835E7490FF9C65A8">
                      <enum>(i)</enum>
                      <text>any felony for conduct relating to wholesale distribution;</text>
                    </clause>
<clause id="H1782CEA5287D4B87BBD27D984BB7FFF9">
                      <enum>(ii)</enum>
                      <text>any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:i">section 301(i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:k">301(k)</cato:entity-ref>; or</text>
                    </clause>
<clause id="H60C99E0B691C4D6CA812CDBD0B228217">
                      <enum>(iii)</enum>
                      <text>any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1365">
                          <external-xref legal-doc="usc" parsable-cite="usc/18/1365">section 1365</external-xref> of title 18, United States Code</cato:entity-ref>, relating to prescription drug product tampering; or</text>
                    </clause>
                  </subparagraph> 
<subparagraph id="H277DFEF280A04347BC63D04233FA8C73">
                    <enum>(B)</enum>
                    <text>has engaged in a pattern of violating the requirements of this section that presents a threat of serious adverse health consequences or death to humans.</text>
                  </subparagraph>
                </paragraph>
              </subsection> 
<subsection commented="no" id="H12ED5D21F0344F4A91122C1B15A2F220">
                <enum>(b)</enum>
                <header>Reporting by licensed wholesale distributors</header> 
<paragraph commented="no" id="H3E445CBA59B64DC39333D62653A4CD62">
                  <enum>(1)</enum>
                  <header>Annual report</header>
                  <text>Beginning not later than 1 year after the date of the enactment of this section, each person engaged in wholesale distribution in interstate commerce shall submit on an annual basis, and update as necessary, a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> including—</text> 
<subparagraph commented="no" id="HC7E8A3CE76664F61A0936DDB61857269">
                    <enum>(A)</enum>
                    <text>the wholesale distributor’s name;</text>
                  </subparagraph> 
<subparagraph commented="no" id="H0AFBE47C3629483DA0930ED5E4DAFD97">
                    <enum>(B)</enum>
                    <text>the wholesale distributor’s address;</text>
                  </subparagraph> 
<subparagraph commented="no" id="H22EF1A21926F4F4595A994E092994ABA">
                    <enum>(C)</enum>
                    <text>a listing of each State in which the wholesale distributor is licensed for wholesale distribution; and</text>
                  </subparagraph> 
<subparagraph commented="no" id="HC656597F3AC44902A511858453F77470">
                    <enum>(D)</enum>
                    <text>any disciplinary actions taken by a State, the Federal Government, or a foreign government during the reporting period against the wholesale distributor.</text>
                  </subparagraph>
                </paragraph> 
<paragraph commented="no" id="HC00526005C304FE799155B98D34C29E8">
                  <enum>(2)</enum>
                  <header>Posting on Internet</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall post on the public Internet Website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> the name of each wholesale distributor, and the State in which each such distributor is licensed, based on reports under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
                </paragraph>
              </subsection> 
<subsection commented="no" id="HBD461E7B4385446CAEB563BDF1C40B38">
                <enum>(c)</enum>
                <header>Preservation of State authority</header>
                <text>This subchapter does not prohibit a State from—</text> 
<paragraph commented="no" id="HD126A8E6B148448A8D50FBEA91A6871A">
                  <enum>(1)</enum>
                  <text>licensing wholesale distributors for the conduct of wholesale distribution activities in the State in accordance with this subchapter; and</text>
                </paragraph> 
<paragraph commented="no" id="HAC5BFBC5879C4111AF8E5CBA22BC13A0">
                  <enum>(2)</enum>
                  <text>collecting fees from wholesale distributors in connection with such licensing,</text>
                </paragraph>
                <continuation-text commented="no" continuation-text-level="subsection">so long as the State does not require such licensure to the extent to which an entity is engaged in third-party logistics provider activities.</continuation-text>
              </subsection> 
<subsection id="H122E7C866DD94C0DAB675C917FAC4533">
                <enum>(d)</enum>
                <header>Definition</header>
                <text>In this section, the term <term>wholesale distribution</term> means the distribution of a drug subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref> to a person other than a consumer or patient, but does not include—</text> 
<paragraph id="HF2306573D48F455F86A94090DEC22905">
                  <enum>(1)</enum>
                  <text>intracompany distribution of any drug between members of an affiliated group (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Internal Revenue Code of 1986/s:1504/ss:a">
                      <external-xref legal-doc="usc" parsable-cite="usc/26/1504">section 1504(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref>);</text>
                </paragraph> 
<paragraph id="H99348CF6F6BD4FA9B705F0B05DCFEC24">
                  <enum>(2)</enum>
                  <text>the distribution of a drug, or an offer to distribute a drug among hospitals or other health care entities which are under common control;</text>
                </paragraph> 
<paragraph id="HD828D8D6657145FBA551602EC11088C5">
                  <enum>(3)</enum>
                  <text>the distribution of a drug or an offer to distribute a drug for emergency medical reasons, including a public health emergency declaration pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:319">section 319 of the Public Health Service Act</cato:entity-ref>, except that a drug shortage not caused by a public health emergency shall not constitute such an emergency medical reason;</text>
                </paragraph> 
<paragraph id="HEB5A4894776A4187B52499FF9017B5F3">
                  <enum>(4)</enum>
                  <text>dispensing of a drug pursuant to a valid prescription executed in accordance with sub<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>;</text>
                </paragraph> 
<paragraph id="H98CB8066C5C74A49BBD934BE1C0E254A">
                  <enum>(5)</enum>
                  <text>the distribution of minimal quantities of drug by a licensed retail pharmacy to a licensed practitioner for office use;</text>
                </paragraph> 
<paragraph id="H53DEB0E4315648BEBD3ECEFCDB438EC6">
                  <enum>(6)</enum>
                  <text>the distribution of a drug or an offer to distribute a drug by a charitable organization to a nonprofit affiliate of the organization to the extent otherwise permitted by law;</text>
                </paragraph> 
<paragraph id="HC480239D25C1412D9C7796CD26BA4172">
                  <enum>(7)</enum>
                  <text>the purchase or other acquisition by a dispenser, hospital, or other health care entity of a drug for use by such dispenser, hospital, or other health care entity;</text>
                </paragraph> 
<paragraph id="HA4D3466F6AE240C899E798DF8FA2B003">
                  <enum>(8)</enum>
                  <text>the distribution of a drug by the manufacturer of such drug;</text>
                </paragraph> 
<paragraph id="H9FAB79960CE14318B40A06962AFB81A4">
                  <enum>(9)</enum>
                  <text>the receipt or transfer of a drug by an authorized third-party logistics provider provided that such third-party logistics provider does not take ownership of the drug;</text>
                </paragraph> 
<paragraph id="HF63E7149FFFE41D18B851EA9151626AB">
                  <enum>(10)</enum>
                  <text>the transport of a drug by a common carrier, provided that the common carrier does not take ownership of the drug;</text>
                </paragraph> 
<paragraph id="H53D9BDCF54EA4442BD9B7FAF32892AEA">
                  <enum>(11)</enum>
                  <text>the distribution of a drug, or an offer to distribute a drug, by an authorized repackager that has taken ownership of the drug and repacked it in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:e" proposed="true">section 582(e)</cato:entity-ref>;</text>
                </paragraph> 
<paragraph id="HFA94BF09E36043FC93684CC11CFE0B52">
                  <enum>(12)</enum>
                  <text>saleable drug returns when conducted by a dispenser in accordance with <external-xref legal-doc="regulation" parsable-cite="cfr/21/203.23">section 203.23</external-xref> of title 21, Code of Federal Regulations (or any successor regulation);</text>
                </paragraph> 
<paragraph commented="no" id="H168D1FAC04E94EB78E2B465227999AD3">
                  <enum>(13)</enum>
                  <text>the distribution of a combination prescription drug product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:20/sp:B/cl:xii" proposed="true">section 581(20)(B)(xii)</cato:entity-ref>;</text>
                </paragraph> 
<paragraph id="H7B310AC340C245E6B8A653F9998838D1">
                  <enum>(14)</enum>
                  <text>the distribution of a medical convenience kit described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:B/cl:xiii" proposed="true">section 581(21)(B)(xiii)</cato:entity-ref>;</text>
                </paragraph> 
<paragraph id="H37A0A2718F8F42AAAD5958645275455E">
                  <enum>(15)</enum>
                  <text>the distribution of an intravenous drug that, by its formulation, is intended for the replenishment of fluids and electrolytes (such as sodium, chloride, and potassium) or calories (such as dextrose and amino acids);</text>
                </paragraph> 
<paragraph id="HCD2EA6B003F54FF3A40521C2780BE928">
                  <enum>(16)</enum>
                  <text>the distribution of an intravenous drug used to maintain the equilibrium of water and minerals in the body, such as dialysis solutions;</text>
                </paragraph> 
<paragraph id="HC58372593BB745388172B3638B0B7339">
                  <enum>(17)</enum>
                  <text>the distribution of a drug that is intended for irrigation or reconstitution, or sterile water, whether intended for such purposes or for injection;</text>
                </paragraph> 
<paragraph id="HD952A73636EB407C875E3588BE5F0BBF">
                  <enum>(18)</enum>
                  <text>the distribution of compressed medical gas (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581/p:21/sp:C" proposed="true">section 581(21)(C)</cato:entity-ref>);</text>
                </paragraph> 
<paragraph id="HD8BFCE6416D84655A11E1DF75CE4CD20">
                  <enum>(19)</enum>
                  <text>facilitating the distribution of a prescription drug product by providing administrative services, such as processing of orders and payments, without physical handling, distribution, or storage of a prescription drug product; or </text>
                </paragraph> 
<paragraph id="H406FE756CE384630A7235067CFDA2BB6">
                  <enum>(20)</enum> 
<subparagraph id="H3DF450E2360E47409C29FE24270FCD0F" display-inline="yes-display-inline">
                    <enum>(A)</enum>
                    <text>the distribution of a product by a dispenser, or a wholesale distributor acting at the direction of the dispenser, to a repackager registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> for the purpose of repackaging the drug for use by that dispenser or another health care entity that is under the dispenser’s ownership or control, so long as the dispenser retains ownership of the prescription drug product; and</text>
                  </subparagraph> 
<subparagraph id="HEA791A816414481F8E98528139665FFF" indent="up1">
                    <enum>(B)</enum>
                    <text display-inline="yes-display-inline">the saleable or nonsaleable return by such repackager of such prescription drug product.</text>
                  </subparagraph>
                </paragraph>
              </subsection> 
<subsection id="HA2A5E5A5A8C9429F8B35FF307BBA7FDA">
                <enum>(e)</enum>
                <header>Effective date</header>
                <text>The standards required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall take effect not later than 2 years after the date of the enactment of this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue the regulations required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">subsection (a)</cato:entity-ref> not later than 1 year after the date of the enactment of this Act.</text>
              </subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection> 
<subsection id="H17B72AF06A924555B1C2B4DB22807674">
        <enum>(b)</enum>
        <header>Conforming amendment</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:804/ss:a/p:5/sp:A">Section 804(a)(5)(A) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/384">
            <cato:entity-ref entity-type="uscode" value="usc/21/384/a/5/A">21 U.S.C. 384(a)(5)(A)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by striking <quote>503(e)(2)(A)</quote> and inserting <quote>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583/ss:a" proposed="true">583(a)</cato:entity-ref>
          </quote>.</text>
      </subsection>
    </section> 
<section id="H1829C4B465AD494D81140487175586F6">
      <enum>5.</enum>
      <header>National licensure standards for third-party logistics providers</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">Subchapter H of chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:4" proposed="true">section 4</cato:entity-ref>, is further amended by adding at the end the following:</text> 
<quoted-block id="HC139CE1D913A4187812955D43483365D" style="OLC"> 
<section id="HB39977EF227E43288645628049ADC216">
          <enum>584.</enum>
          <header>National licensure standards for third-party logistics providers</header> 
<subsection id="H5BA415E865C54C1D9751C4A20AA303C0">
            <enum>(a)</enum>
            <header>License requirement</header>
            <text>No facility may engage in the activities of a third-party logistics provider in any State unless—</text> 
<paragraph id="H50D49339794E476A9054650BC53400F8">
              <enum>(1)</enum>
              <text>the facility is licensed—</text> 
<subparagraph id="HDE8057D0BE7C4233980834DACB6D9F5A">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">by the State from which the drug is distributed by the third-party logistics provider in accordance with a qualified licensing program, if the State has such a program; or</text>
              </subparagraph> 
<subparagraph id="HC45190F3C5DB4AB1B0E1DB890A6826AE">
                <enum>(B)</enum>
                <text>by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under this section, if the State from which the drug is distributed does not have such a program; and</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H872673C33FC34D6784370CF2D254E238">
              <enum>(2)</enum>
              <text display-inline="yes-display-inline">if the drug is distributed interstate and the facility is not licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:a/p:1/sp:B" proposed="true">paragraph (1)(B)</cato:entity-ref>, registers with the State into which the drug is distributed if such State requires such registration.</text>
            </paragraph>
          </subsection> 
<subsection commented="no" id="H7DFC4CDDE5384E0F8A47EBCA1A4FBDC4">
            <enum>(b)</enum>
            <header>Reporting by licensed third-Party logistics providers</header> 
<paragraph commented="no" id="HB8B44214FA814A15846C1BD3EB170BC6">
              <enum>(1)</enum>
              <header>Annual report</header>
              <text>Beginning not later than 1 year after the date of the enactment of this section, each facility engaged in the activities of a third-party logistics provider shall submit on an annual basis, and update as necessary, a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> including—</text> 
<subparagraph commented="no" id="HE170D6D282764EBF908A15C22953CF04">
                <enum>(A)</enum>
                <text>the facility’s name;</text>
              </subparagraph> 
<subparagraph commented="no" id="H9E82F5AD4DBF4B109292DC9C36BA4AB5">
                <enum>(B)</enum>
                <text>the facility’s address;</text>
              </subparagraph> 
<subparagraph commented="no" id="H4DE8968713084BE0837E418D7A843DC2">
                <enum>(C)</enum>
                <text>a listing of each jurisdiction (whether State or Federal) in which the facility is licensed for third-party logistics provider activities; and</text>
              </subparagraph> 
<subparagraph commented="no" id="H2B6081B68C1E48FEABBA2D31FB17DC45">
                <enum>(D)</enum>
                <text>any disciplinary actions taken by a State or Federal licensing authority during the reporting period against the facility.</text>
              </subparagraph>
            </paragraph> 
<paragraph commented="no" id="H70F60130472C40559E5C6549C8C1D0C4">
              <enum>(2)</enum>
              <header>Posting on Internet</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall post on the public Internet Website of the Food and Drug Administration the name of each third-party logistics provider, and each jurisdiction (whether State or Federal) in which the provider is licensed, based on reports under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
            </paragraph>
          </subsection> 
<subsection commented="no" id="H98B5E21967824B2B91ACD4CE7E609274">
            <enum>(c)</enum>
            <header>Preservation of State authority</header>
            <text>This subchapter does not prohibit a State from—</text> 
<paragraph commented="no" id="H7B43ECB57BE94C0BBCE5F7B66F1B5914">
              <enum>(1)</enum>
              <text>licensing third-party logistic providers for the conduct of third-party logistics provider activities in the State in accordance with this subchapter; and</text>
            </paragraph> 
<paragraph commented="no" id="H60B9F38CEA1E410BA02FE1BEE40A336C">
              <enum>(2)</enum>
              <text>collecting fees from third-party logistics providers in connection with such licensing,</text>
            </paragraph>
            <continuation-text commented="no" continuation-text-level="subsection">so long as the State does not require such licensure to the extent to which an entity is engaged in wholesale distribution.</continuation-text>
          </subsection> 
<subsection id="H2C45619F20E84100A8C51FD73F678EC0">
            <enum>(d)</enum>
            <header>Costs</header> 
<paragraph id="H97C1439B8C654FA2B02CBCA5B8801BB5">
              <enum>(1)</enum>
              <header>Authorized licensure fees</header>
              <text>In the case of a facility engaging in the activities of a third-party logistics provider licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess and collect a reasonable fee in an amount equal to the costs to the Federal Government of establishing and administering the licensure program established, and conducting period inspections, under this section.</text>
            </paragraph> 
<paragraph id="H315CABAA43AA4611AED7EFD64830051F">
              <enum>(2)</enum>
              <header>Adjustment</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall adjust the amount of the fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> on an annual basis, if necessary, to generate an amount of revenue equal to the costs referred to in such paragraph.</text>
            </paragraph> 
<paragraph id="HCE3ACCFBBAC64EF3925EDF51A8A84BDF">
              <enum>(3)</enum>
              <header>Availability</header>
              <text display-inline="yes-display-inline">Fees assessed and collected under this subsection shall be available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees shall remain available until expended.</text>
            </paragraph>
          </subsection> 
<subsection id="H7679C8082EB54F2E80C728E32DB0941A">
            <enum>(e)</enum>
            <header>License regulations</header> 
<paragraph id="H7075BDEE20B641F89A60322841701602">
              <enum>(1)</enum>
              <header>In general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, by regulation, standards, terms, and conditions for licensing persons to engage in third-party logistics provider activities.</text>
            </paragraph> 
<paragraph id="HDE825B77EA8C4CB7A9B2301E2EF27D54">
              <enum>(2)</enum>
              <header>Content</header>
              <text>The regulations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:e/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall—</text> 
<subparagraph id="HAB92966E11C74AD7B0AE13C0C01E72F0">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">include standards relating to eligibility for, and revocation and reissuance of, licenses;</text>
              </subparagraph> 
<subparagraph id="H2000687BC4184B569463E44CB6AE6EA9">
                <enum>(B)</enum>
                <text>establish a process by which the applicable licensing authority will, upon request by a third-party logistics provider that is accredited by a third-party accreditation program approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, issue a license to the provider;</text>
              </subparagraph> 
<subparagraph id="H0621FD0B19964A1AA712F050950B9179">
                <enum>(C)</enum>
                <text>establish a process by which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a license to a third-party logistics provider if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> is not able to approve a third-party accreditation program because no such program meets the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s requirements necessary for approval of such a third-party accreditation program;</text>
              </subparagraph> 
<subparagraph id="H0CDE027834414704956B6DC141049E7A">
                <enum>(D)</enum>
                <text>require that the third-party logistics provider comply with storage practices, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, at the provider’s facilities, including—</text> 
<clause id="H84A0EF50C0334B638D5F42139DA1DD9F">
                  <enum>(i)</enum>
                  <text>maintaining access to warehouse space of suitable size to facilitate safe operations, including a suitable area to quarantine suspect prescription drug product;</text>
                </clause> 
<clause id="HB24BB0A291F44ABA88711FB974C136AC">
                  <enum>(ii)</enum>
                  <text>maintaining adequate security; and</text>
                </clause> 
<clause id="H525E52B1DF4A4C4798BAD5B93917EEDE">
                  <enum>(iii)</enum>
                  <text>having written policies and procedures to—</text> 
<subclause id="H764130941F074E7C8FC02DE21517D5C7">
                    <enum>(I)</enum>
                    <text>address receipt, security, storage, inventory, shipment, and distribution of a prescription drug product;</text>
                  </subclause> 
<subclause id="HD7C16F21980A4E4D80160939D13EB1D3">
                    <enum>(II)</enum>
                    <text>identify, record, and report confirmed losses or thefts in the United States;</text>
                  </subclause> 
<subclause id="HE95CC9A880194D318CF74562C95969D2">
                    <enum>(III)</enum>
                    <text>correct errors and inaccuracies in inventories;</text>
                  </subclause> 
<subclause id="HFEA0EF21635E47C4A81F118E251620FC">
                    <enum>(IV)</enum>
                    <text>provide support for manufacturer recalls;</text>
                  </subclause> 
<subclause id="H2C1637D786E34ECA92312A6977D33EC9">
                    <enum>(V)</enum>
                    <text>prepare for, protect against, and address any reasonably foreseeable crisis that affects security or operation at the facility, such as a strike, fire, or flood;</text>
                  </subclause> 
<subclause id="HD5683D273CDC470D8B4D2B0B513EDD92">
                    <enum>(VI)</enum>
                    <text>ensure that any expired prescription drug product is segregated from other prescription drug products and returned to the manufacturer or repackager or destroyed;</text>
                  </subclause> 
<subclause id="HCD92BE4591374717A631EBB4C05434EA">
                    <enum>(VII)</enum>
                    <text>maintain the capability to electronically trace the receipt and outbound distribution of a prescription drug product, and supplies and records of inventory; and</text>
                  </subclause> 
<subclause id="HF5C26BE3BE7D44E2B85D3B0FC0C05429">
                    <enum>(VIII)</enum>
                    <text>quarantine or destroy a suspect prescription drug product if directed to do so by the respective manufacturer, wholesale distributor, dispenser, or an authorized government agency;</text>
                  </subclause>
                </clause>
              </subparagraph> 
<subparagraph id="HE886358FB12E432E93C44B06A1289FCC">
                <enum>(E)</enum>
                <text>provide for periodic inspection, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, of such facility warehouse space to ensure compliance with this section;</text>
              </subparagraph> 
<subparagraph id="HCC32836553CC40A5B782AED812DD5166">
                <enum>(F)</enum>
                <text>prohibit a facility from having as a manager or designated representative anyone convicted of any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:i">section 301(i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:k">301(k)</cato:entity-ref> or any felony violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1365">
                    <external-xref legal-doc="usc" parsable-cite="usc/18/1365">section 1365</external-xref> of title 18, United States Code</cato:entity-ref>, relating to prescription drug product tampering;</text>
              </subparagraph> 
<subparagraph id="H98975C5754184E159039507929CB7FB2">
                <enum>(G)</enum>
                <text>perform mandatory background checks of the provider’s facility managers or designated representatives of such managers;</text>
              </subparagraph> 
<subparagraph id="HE6874AC3B43A4C0A977DD611E70E0CB5">
                <enum>(H)</enum>
                <text>require a third-party logistics provider to provide to the applicable licensing authority, upon the authority’s request, a list of all prescription drug product manufacturers, wholesale distributors, and dispensers for whom the third-party logistics provider provides services at the provider’s facilities; and</text>
              </subparagraph> 
<subparagraph id="HA9910140D2994862AEF36000A8F12952">
                <enum>(I)</enum>
                <text>include procedures under which any third-party logistics provider license—</text> 
<clause id="HC4EA679CC1B742EFB322438B778F67ED">
                  <enum>(i)</enum>
                  <text>will expire on the date that is 3 years after issuance of the license; and</text>
                </clause> 
<clause id="H21C4442E4BEA469F9CDC13749322CF59">
                  <enum>(ii)</enum>
                  <text>may be renewed for additional 3-year periods.</text>
                </clause>
              </subparagraph>
            </paragraph>
          </subsection> 
<subsection id="H0907028A725748839F0FCD3398AF81D5">
            <enum>(f)</enum>
            <header>Validity of license</header>
            <text>A license issued under this section shall remain valid as long as such third-party logistics provider remains accredited by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, subject to renewal under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d" proposed="true">subsection (d)</cato:entity-ref>. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that the third-party accreditation program demonstrates that all applicable requirements for licensure under this section are met, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a license under this section to a third-party logistics provider receiving accreditation.</text>
          </subsection> 
<subsection id="H1283E043AB9941F9B6890101AFF65F08">
            <enum>(g)</enum>
            <header>Qualified licensing program defined</header>
            <text>In this section, the term <term>qualified licensing program</term> means a program meeting the requirements of this section and the regulations thereunder.</text>
          </subsection> 
<subsection id="HF906FDC60C164E909AD1600BB7F6DD8E">
            <enum>(h)</enum>
            <header>Effective date</header>
            <text>The requirements of this section shall take effect not later than 1 year after the date of the enactment of this section. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue the regulations required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584/ss:d" proposed="true">subsection (d)</cato:entity-ref> not later than 180 days after the date of the enactment of this section.</text>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section> 
<section id="H49245758A244454BA888E66E49BE87D3">
      <enum>6.</enum>
      <header>Penalties</header> 
<subsection id="H752767F922D549918572509B430C0F25">
        <enum>(a)</enum>
        <header>Prohibited acts</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:t">Section 301(t) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
            <cato:entity-ref entity-type="uscode" value="usc/21/331/t">21 U.S.C. 331(t)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by striking <quote>or the distribution of drugs in violation of section 503(e) or the failure to otherwise comply with the requirements of section 503(e)</quote> and inserting <quote>the failure to comply with any requirement of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>, engaging in the wholesale distribution of a drug in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref> or the failure to otherwise comply with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref>, or engaging in the activities of a third-party logistics provider in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref> or the failure to otherwise comply with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">section 584</cato:entity-ref>
          </quote>.</text>
      </subsection> 
<subsection id="H189C0214DE8548ED8C80F2AABDAD4404">
        <enum>(b)</enum>
        <header>Enhanced penalty for knowing unlicensed activities</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:303/ss:b/p:1/sp:D">Section 303(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/333">
            <cato:entity-ref entity-type="uscode" value="usc/21/333/b/1/D">21 U.S.C. 333(b)(1)(D)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by striking <quote>503(e)(2)(A)</quote> and inserting <quote>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">583</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref>
          </quote>.</text>
      </subsection> 
<subsection id="HC705A2E85F2E430382C3150CA89DF922">
        <enum>(c)</enum>
        <header>Misbranding</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">Section 502 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
            <cato:entity-ref entity-type="uscode" value="usc/21/352">21 U.S.C. 352</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block id="H6682407DBE804729AF389F210C0AA722" style="OLC"> 
<subsection id="HE7F7A0E1656A452E9E43A0471C25350D">
            <enum>(bb)</enum>
            <text>If it is a drug and it fails to bear a prescription drug product identifier as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582" proposed="true">section 582</cato:entity-ref>.</text>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
    </section> 
<section id="HC438ED95D59F422AB9C707A32D1F9C46">
      <enum>7.</enum>
      <header>Uniform national policy</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:H" proposed="true">Subchapter H of chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:5" proposed="true">section 5</cato:entity-ref>, is further amended by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H204B60DC95AD41068ECA554CF6B63EFF" style="OLC"> 
<section id="H3FB66B0B18414B828ECC5B8C214D1130">
          <enum>585.</enum>
          <header>Uniform national policy</header> 
<subsection id="HD265B4EA81054345A2A100CB0EED668E">
            <enum>(a)</enum>
            <header>Preemption of State prescription drug product tracing and other requirements</header>
            <text>Beginning on the date of the enactment of the <short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
              </short-title>, no State or political subdivision of a State may establish or continue in effect any requirements for tracing drugs through the distribution system (including any requirements with respect to paper or electronic pedigrees, track and trace, statements of distribution history, transaction history, or transaction statements, or verification, investigation, disposition, alerts, or recordkeeping relating to the pharmaceutical distribution supply chain system) that—</text> 
<paragraph id="H0A09772EC6604FC89CF50C917AB8F640">
              <enum>(1)</enum>
              <text>are inconsistent with, more stringent than, or in addition to any requirements applicable under this Act; or</text>
            </paragraph> 
<paragraph id="H3FEB4EDDEC1142AABC089EDC3930D63C">
              <enum>(2)</enum>
              <text>are inconsistent with any applicable waiver, exception, or exemption issued by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:582/ss:a" proposed="true">section 582(a)</cato:entity-ref>.</text>
            </paragraph>
          </subsection> 
<subsection id="H52A822BF43034EFCB428AB21E9375D61">
            <enum>(b)</enum>
            <header>Standards or licensure</header> 
<paragraph id="H6A5D194B16F24136B08B763FEC8272BF">
              <enum>(1)</enum>
              <header>In general</header>
              <text>Beginning on the date of the enactment of <short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013" proposed="true">Safeguarding America’s Pharmaceuticals Act of 2013</cato:entity-ref>
                </short-title>, no State or political subdivision of a State may establish or continue any standards, requirements, or regulations with respect to wholesale drug distributor or third-party logistics provider licensure which are inconsistent with, less stringent than, in addition to, or more stringent than, the standards and requirements under this Act.</text>
            </paragraph> 
<paragraph id="H7CC821866E6544E184E8D2872727DC71">
              <enum>(2)</enum>
              <header>Licensing fees</header>
              <text display-inline="yes-display-inline">
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b/p:1" proposed="true">Paragraph (1)</cato:entity-ref> does not affect the authority of a State to collect fees from wholesale drug distributors or third-party logistics providers in connection with State licensing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref> pursuant to a licensing program meeting the requirements of such sections.</text>
            </paragraph> 
<paragraph id="H291F39228A48405EAD6345F59D228C4C">
              <enum>(3)</enum>
              <header>Enforcement, suspension, and revocation of licenses</header>
              <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:585/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>, a State—</text> 
<subparagraph id="H13BE68BA2903443B9A22729F781B8308">
                <enum>(A)</enum>
                <text>may take administrative action, including fines, to enforce a licensure requirement promulgated by the State in accordance with this Act;</text>
              </subparagraph> 
<subparagraph id="HDF56F2BF0312424BB6E044988A3B1FC8">
                <enum>(B)</enum>
                <text>may provide for the suspension or revocation of licenses issued by the State for violations of the laws of such State;</text>
              </subparagraph> 
<subparagraph id="H2F9BAE6E213D422C8C0CCBD143CF421C">
                <enum>(C)</enum>
                <text>upon conviction of a person for a violation of Federal, State, or local controlled substance laws or regulations, may provide for fines, imprisonment, or civil penalties; and</text>
              </subparagraph> 
<subparagraph commented="no" id="H87AF0F1A5BBC4E429CADE9464EF40DB9">
                <enum>(D)</enum>
                <text>may regulate activities of entities licensed pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:583" proposed="true">section 583</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:584" proposed="true">584</cato:entity-ref> in a manner that is consistent with the provisions of this subchapter.</text>
              </subparagraph>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section> 
<section id="HB8F1F9C2B1C445ADAF7457B57816C0EB">
      <enum>8.</enum>
      <header>Electronic labeling</header> 
<subsection id="H30A69E639A7D4F9085C167C13A82F186">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f">Section 502(f) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
            <cato:entity-ref entity-type="uscode" value="usc/21/352/f">21 U.S.C. 352(f)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following new sentence: <quote>Required labeling (other than immediate container or carton labels) that is intended for use by a physician, a pharmacist, or another health care professional, and that provides directions for human use of a drug subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503/ss:b/p:1">section 503(b)(1)</cato:entity-ref>, may (except as necessary to mitigate a safety risk, as specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in regulation) be made available by electronic means instead of paper form, provided that such labeling complies with all applicable requirements of law, the manufacturer or distributor, as applicable, affords health care professionals and authorized dispensers (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:581" proposed="true">section 581</cato:entity-ref>) the opportunity to request the labeling in paper form, and after such a request the manufacturer or distributor promptly provides the requested information without additional cost.</quote>.</text>
      </subsection> 
<subsection id="H9A8011CA271644A59D9CC6EA5B251F41">
        <enum>(b)</enum>
        <header>Regulations</header>
        <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref> shall promulgate regulations implementing the amendment made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:8/ss:a" proposed="true">subsection (a)</cato:entity-ref>.</text>
      </subsection> 
<subsection id="H96C5113CECE5472CBBDFEA31583602C3">
        <enum>(c)</enum>
        <header>Application</header>
        <text>The last sentence of <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f">section 502(f) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
            <cato:entity-ref entity-type="uscode" value="usc/21/352/f">21 U.S.C. 352(f)</cato:entity-ref>
          </external-xref>)</cato:entity>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:8/ss:a" proposed="true">subsection (a)</cato:entity-ref>, shall apply beginning on the earlier of—</text> 
<paragraph id="HAEA1CC06910243BBA75FC5AC7194FC21">
          <enum>(1)</enum>
          <text>the effective date of final regulations promulgated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Safeguarding America’s Pharmaceuticals Act of 2013/s:8/ss:b" proposed="true">subsection (b)</cato:entity-ref>; or</text>
        </paragraph> 
<paragraph id="H0228B6D7A3D44564B6498989D4225750">
          <enum>(2)</enum>
          <text>the day that is 180 days after the date of enactment of this Act.</text>
        </paragraph>
      </subsection>
    </section> 
</legis-body> <attestation>
    <attestation-group>
      <attestation-date date="20130603" chamber="House">Passed the House of Representatives June 3, 2013.</attestation-date>
      <attestor display="no">Karen L. Haas,</attestor>
      <role>Clerk.</role>
    </attestation-group>
  </attestation>
<endorsement display="yes"/>
</bill>
</doc>